GSK plc 6-K, filed Apr 30, 2025
GSK plc (GSK)
6-K
2025-04-30
For: 2025-04-30
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on April 30, 2025.
|
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK makes strong
start to 2025 with growth in sales, profits and
earnings
|
|
|
|
Specialty Medicines growth drives Q1 performance
|
|
|
●
|
Total
Q1 sales £7.5 billion +2% AER; +4% CER
|
|
●
|
Specialty
Medicines sales £2.9 billion (+17%); Respiratory, Immunology
and Inflammation £0.8 billion (+28%); Oncology £0.4
billion (+53%); HIV sales £1.7 billion (+7%)
|
|
●
|
Vaccines
sales £2.1 billion (-6%); Shingrix £0.9 billion (-7%);
Meningitis vaccines £0.4 billion (+20%); and Arexvy £0.1 billion
(-57%)
|
|
●
|
General
Medicines sales £2.5 billion (stable); Trelegy £0.7 billion
(+15%)
|
|
●
|
Total
operating profit +50% and Total EPS +56% driven by lower CCL
charges
|
|
●
|
Core operating profit +5% and Core EPS +5% reflecting strong
Specialty Medicines performance and disciplined increased
investment in R&D portfolio progression, new asset launches and
growth assets
|
|
●
|
Cash
generated from operations exceeded £1 billion with free cash
flow of £0.7 billion
|
|
(Financial Performance – Q1 2025 results unless otherwise
stated, growth % and commentary at CER as defined on page
44).
|
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
Turnover
|
7,516
|
|
2
|
|
4
|
|
Total
operating profit
|
2,216
|
|
49
|
|
50
|
|
Total
operating margin %
|
29.5%
|
|
9.2ppts
|
|
9.0ppts
|
|
Total
EPS
|
39.7p
|
|
55
|
|
56
|
|
Core
operating profit
|
2,533
|
|
4
|
|
5
|
|
Core
operating margin %
|
33.7%
|
|
0.5ppts
|
|
0.3ppts
|
|
Core
EPS
|
44.9p
|
|
4
|
|
5
|
|
Cash
generated from operations
|
1,301
|
|
16
|
|
|
|
|
|
|
Pipeline progress and investment delivering future growth
opportunities:
|
|
|
5 major new FDA product approvals expected in 2025:
|
|
|
●
|
Q1 2025
approvals: Penmenvy,
meningitis vaccine; Blujepa, first-in-class antibiotic
treatment for uUTIs
|
|
●
|
Positive
ACIP recommendations for Penmenvy (and Arexvy (adults 50-59))
|
|
●
|
Further
approvals expected for: Nucala (COPD); Blenrep (multiple myeloma); and
depemokimab (severe asthma and nasal polyps)
|
|
14 key opportunities expected to launch 2025-2031 each with PYS
potential above £2 billion
|
|
|
●
|
Data
presented at CROI for VH184, VH499 and N6LS support development
plans for ULA HIV regimens
|
|
●
|
Breakthrough
designation granted for GSK'227 B7H3 ADC for 2L
osteosarcoma
|
|
●
|
Pivotal/Phase
III trials expected to start in 2025 for: Respiratory (depemokimab
COPD programme - ENDURA); Oncology (GSK'227 B7H3 ADC ES-SCLC;
IDRx-42 2L GIST; Ojjaara
(MDS)); and HIV (Q4M treatment)
|
|
Investment in targeted business development continues
|
|
|
●
|
Acquisition
of IDRx completed
|
|
●
|
New
partnership with ABL Bio in neurodegenerative diseases; and novel
research collaboration with UK Dementia Research Institute &
HDRUK to investigate shingles vaccination with prevention of
dementia
|
|
|
|
|
Continued commitment to shareholder returns
|
|
|
●
|
Dividend
declared of 16p for Q1 2025; 64p expected for full year
2025
|
|
●
|
£273
million of shares bought back as part of the £2 billion share
buyback programme commenced in Q1 2025
|
|
|
|
|
Confident for delivery of 2025 guidance
|
|
|
●
|
Continue
to expect 2025 turnover growth 3% to 5%; Core operating profit
growth 6% to 8%; Core EPS growth 6% to 8%
|
Guidance all at CER
|
|
|
Emma Walmsley, Chief Executive Officer, GSK:
"GSK
continues to make strong progress, demonstrating the quality,
strength and resilience of our portfolio. Specialty Medicines, our
largest business, delivered strong sales contributions in the
quarter and R&D progress continued, with two of the five FDA
product approvals expected this year now secured, and the
acquisition of a promising new oncology asset. We are very focused
on preparing for launches of Blenrep, Nucala and depemokimab, and pivotal
trials for potential new medicines in respiratory, oncology, HIV
and hepatitis. This momentum, together with the strength of our
portfolio and proven ability to drive operating leverage, underpin
our confidence in guidance for the year and our longer-term
outlooks."
|
The Total results are presented in summary above and on page 7 and
Core results reconciliations are presented on pages 19 and 20. Core
results are a non-IFRS measure that may be considered in addition
to, but not as a substitute for, or superior to, information
presented in accordance with IFRS. The following terms are defined
on pages 44-45: Core results, AER% growth, CER% growth, turnover;
and other non-IFRS measures. GSK provides guidance on a Core
results basis only for the reasons set out on page 17. All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance and
outlooks, assumptions and cautionary statements’ on page 46.
Abbreviations are defined on page 50.
2025 Guidance
GSK
affirms its full-year 2025 guidance at constant exchange rates
(CER).
|
|
|
Turnover is expected to increase between 3 to 5 per
cent
|
|
Core operating profit
is expected to increase between 6 to 8
per cent
|
|
Core earnings per share
is expected to increase between 6 to 8
per cent
|
This
guidance is supported by the following turnover expectations for
full-year 2025 at CER
|
|
|
|
|
Specialty Medicines
|
–
|
expected
increase of a low double-digit per
cent in turnover
|
|
Vaccines
|
–
|
expected
decrease of a low single-digit per
cent in turnover
|
|
General Medicines
|
–
|
expected
to be broadly stable for
turnover
|
Core
operating profit is expected to grow between 6 to 8 per cent at
CER. GSK expects to deliver leverage at a gross margin level due to
improved product mix from Specialty Medicines growth and continued
operational efficiencies. In addition, GSK anticipates further
leverage in Operating profit as we continue to take a returns-based
approach to SG&A investments. Royalty income is now expected to
be higher than previously guided at £750-800 million,
including an IP settlement agreed in April. This additional income
will be reinvested in the pipeline this year.
Core
earnings per share is expected to increase between 6 to 8 per cent
at CER, in line with Core operating profit growth, reflecting
higher interest charges and the tax rate which is expected to rise
to around 17.5%, offset by the expected benefit of up to 1% from
the share buyback programme. Expectations for non-controlling
interests remain unchanged relative to 2024.
Tariffs
GSK
notes that the US Administration has initiated an investigation
under Section 232 of the Trade Expansion Act to determine the
effects on national security of imports of pharmaceutical products.
The company is well positioned to respond to the potential
financial impact of sector-specific tariffs, should they be
implemented, with mitigation options identified in the supply chain
and productivity initiatives. The company will continue to monitor
and review developments related to this situation.
Dividend policy
The
Dividend policy and the expected pay-out ratio remain unchanged.
Consistent with this, GSK has declared a dividend for Q1 2025 of
16p per share. GSK's future dividend policy and guidance regarding
the expected dividend pay-out in 2025 are provided on page
31.
GSK has
commenced a £2 billion share buyback programme, to be
implemented over the period to the end of Q2 2026.
2021-2026 and 2031 Outlooks
In
February 2025 GSK set out improved outlooks for 2031. Please see
2024 full year and fourth quarter results on gsk.com(1).
Exchange rates
If
exchange rates were to hold at the closing rates on 24 April 2025
($1.33/£1, €1.17/£1 and Yen 190/£1) for the
rest of 2025, the estimated impact on 2025 Sterling turnover growth
for GSK would be -2% and if exchange gains or losses were
recognised at the same level as in 2024, the estimated impact on
2025 Sterling Core Operating Profit growth for GSK would be
-4%.
Results presentation
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Emma Walmsley, CEO, at 12 noon
BST (US EDT at 07.00 am) on 30 April 2025. Presentation
materials will be published on www.gsk.com prior to the webcast and
a transcript of the webcast will be published
subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
(1)
https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf
|
|
|
Performance:
turnover
|
|
|
|
|
|
|
|
|
Turnover
|
Q1 2025
|
||||
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
HIV
|
1,714
|
|
6
|
|
7
|
|
Respiratory,
Immunology and Inflammation
|
804
|
|
26
|
|
28
|
|
Oncology
|
415
|
|
52
|
|
53
|
|
Specialty Medicines
|
2,933
|
|
16
|
|
17
|
|
Shingles
|
867
|
|
(8)
|
|
(7)
|
|
Meningitis
|
350
|
|
17
|
|
20
|
|
RSV
(Arexvy)
|
78
|
|
(57)
|
|
(57)
|
|
Influenza
|
1
|
|
(92)
|
|
(92)
|
|
Established
Vaccines
|
799
|
|
(5)
|
|
(3)
|
|
Vaccines
|
2,095
|
|
(8)
|
|
(6)
|
|
Respiratory
|
1,710
|
|
(1)
|
|
1
|
|
Other
General Medicines
|
778
|
|
(7)
|
|
(3)
|
|
General Medicines
|
2,488
|
|
(3)
|
|
–
|
|
Total
|
7,516
|
|
2
|
|
4
|
|
By Region:
|
|
|
|
|
|
|
US
|
3,752
|
|
5
|
|
4
|
|
Europe
|
1,749
|
|
8
|
|
11
|
|
International
|
2,015
|
|
(6)
|
|
(2)
|
|
Total
|
7,516
|
|
2
|
|
4
|
|
|
|
Financial Performance – Q1 2025 results unless otherwise
stated, growth % and commentary at CER.
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
£m
|
AER
|
CER
|
|
Specialty Medicines
|
2,933
|
16%
|
17%
|
Specialty Medicines sales grew by double-digit percentages in the
quarter, reflecting continued growth across disease areas, with
strong performances in HIV, Respiratory, Immunology and
Inflammation, and Oncology.
|
|
|
|
|
|
HIV
|
1,714
|
6%
|
7%
|
HIV
sales grew by 7% this quarter with the US growing at 9%. This was
driven by a 9 percentage point increase in patient demand from
Cabenuva, Apretude and
Dovato reflecting strong
market share growth. Growth in the quarter also benefited from
customer ordering patterns, offset by unfavourable price impacts
from channel mix adjustments and the impact of IRA Medicare Part D
redesign.
|
|
|
|
|
|
Oral
2DR
|
728
|
14%
|
15%
|
Sales
of Oral 2DR now represent 42% of the total HIV portfolio.
Dovato, the first and only
once-daily Oral 2DR for the treatment of HIV infection in both
treatment naive and virally suppressed adults and adolescents
continues to be the largest product in the HIV portfolio with sales
of £570 million in the quarter and growing 19%.
|
|
|
|
|
|
Long-Acting
|
383
|
43%
|
43%
|
Long-Acting
sales in the quarter now represent 22% of the total HIV portfolio
(29% in the US) and contributed 100% of the total HIV growth in Q1
2025. Cabenuva, the only complete long-acting injectable regimen
for HIV treatment reached sales of £294 million in the
quarter, growing 38% due to strong patient demand across US and
Europe. Apretude, the first long-acting injectable option for HIV
prevention delivered sales of £89 million in the quarter,
growing 63% compared to Q1 2024.
|
|
|
|
|
|
Respiratory,
Immunology and Inflammation
|
804
|
26%
|
28%
|
Sales
primarily comprised contributions from Nucala in respiratory and Benlysta in immunology. Double-digit
sales growth in the quarter was delivered for both Nucala and Benlysta, driven by patient demand
globally across US, European and International markets. Growth in
the quarter was also positively affected by the impacts of channel
inventory reductions in the US in Q1 2024 for both Nucala and Benlysta.
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
£m
|
AER
|
CER
|
|
Nucala
|
444
|
19%
|
21%
|
Sales
growth in the quarter was driven by strong performance across all
regions, reflecting higher patient demand for treatments addressing
eosinophilic-led disease. Growth in the quarter in the US was
predominantly driven by the impacts of channel inventory reductions
occurring in 2024, with further underlying double digit volume
increases being largely offset by unfavourable price impacts,
including the impact of IRA Medicare Part D redesign.
|
|
|
|
|
|
Benlysta
|
359
|
38%
|
39%
|
Sales
of Benlysta, a monoclonal
antibody treatment for lupus, grew in the quarter representing
strong demand and volume growth in US, European and International
regions, with bio-penetration rates having increased across many
markets. Growth in the US was also positively impacted by price
favourability, as well as the impacts of channel inventory
reductions that occurred in Q1 2024.
|
|
|
|
|
|
Oncology
|
415
|
52%
|
53%
|
Oncology
sales are largely comprised of sales from Jemperli, Zejula and Ojjaara/Omjjara. Strong sales growth in
the quarter was driven in particular by increasing patient demand
for Jemperli and
Ojjaara/Omjjara.
|
|
|
|
|
|
Jemperli
|
174
|
>100%
|
>100%
|
Sales
of Jemperli grew strongly
in the quarter, driven largely by continued volume growth in the US
following Q3 2024 FDA approval expanding the indication to include
all adult patients with primary advanced or recurrent endometrial
cancer. Europe and International regions increasingly contribute to
sales and growth, with Jemperli now available in over 30
countries worldwide.
|
|
|
|
|
|
Zejula
|
131
|
(7%)
|
(5%)
|
Sales
of Zejula, a PARP inhibitor
treatment for ovarian cancer, decreased in the quarter, driven
largely by a double-digit decrease in the US. Performance in the US
was adversely impacted by price unfavourability, driven in part by
ongoing channel pricing pressure, and also from impacts of
favourable Q1 2024 comparator channel mix adjustments.
|
|
|
|
|
|
Ojjaara/Omjjara
|
112
|
>100%
|
>100%
|
Sales
of Ojjaara/Omjjara, a
treatment for myelofibrosis patients with anaemia, grew strongly in the quarter largely
driven by the US with continued patient uptake and volume
growth. Sales in the quarter included increasing
contributions from Europe and International regions, following the
recent launch in Japan in Q3 2024, and with further new launches
including Spain and Italy in Q1 2025.
|
|
|
|
|
|
Vaccines
|
2,095
|
(8%)
|
(6%)
|
Vaccines sales decreased in the quarter, primarily impacted by
lower demand for Arexvy related to a more limited ACIP recommendation
combined with lower demand for Shingrix in the US and International. Meningitis vaccines
continued to show strong demand with double-digit sales
growth.
|
|
|
|
|
|
Shingles
|
867
|
(8%)
|
(7%)
|
Sales
of Shingrix decreased in
the quarter, with lower sales in the US and International partially
offset by growth in Europe.
The US
cumulative immunisation rate reached 41%, up five percentage points
compared to 12 months earlier(1). Sales decreased
by 21% in the quarter due to the continuing slowdown in the pace of
penetration of harder-to-reach unvaccinated consumers, as well as
higher channel inventory consumption.
Sales
of Shingrix decreased in
International in the quarter, reflecting a strong Q1 2024
comparator driven by rapid uptake from the national immunisation
programme in Australia. Performance was also impacted by lower
current quarter supply to our co-promotion partner in
China.
In
Europe, Shingrix sales grew
in the quarter driven by new launch uptake in France together with
expanded public funding and higher private market demand across
several countries.
Shingrix is now launched in 54 countries, with markets
outside the US representing 57% of Q1 2025 global sales (2024:
50%). The overwhelming majority of ex-US Shingrix opportunity is concentrated in
10 markets where the average immunisation rate is around 8% with
significantly higher uptake in funded cohorts.
|
|
|
|
|
|
Meningitis
|
350
|
17%
|
20%
|
In the
quarter, both key Meningitis vaccines continued to grow strongly,
achieving double-digit growth. Bexsero, a vaccine against meningitis
B, grew 20% primarily driven by continued uptake following the
recommendation in Germany together with the implementation of
mandatory newborn vaccination in France and public funding in
Switzerland. Menveo, a
vaccine against meningitis ACWY, grew mainly due to the timing of
deliveries in International.
Footnote: (1) Based on data from IQVIA up until the end of Q4
2024
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
£m
|
AER
|
CER
|
|
RSV (Arexvy)
|
78
|
(57%)
|
(57%)
|
Arexvy sales decreased in the quarter. US
sales declined due to lower demand partly related to a more limited
recommendation from ACIP for individuals aged 60 to 74.
Arexvy maintained the
market leading position in retail where the overwhelming majority
of doses are administered.
Growth
in Europe was driven by launch uptake following recommendation and
reimbursement in Germany offset by a decrease in International
reflecting lower demand in Saudi Arabia and Canada. While
Arexvy is approved in 66
markets globally, 18 countries had national RSV vaccination
recommendations for older adults and 6, including the US, had
reimbursement programmes for Arexvy in place at the quarter
end.
|
|
|
|
|
|
Established
Vaccines
|
799
|
(5%)
|
(3%)
|
Established
Vaccines sales decreased primarily in International, which was
impacted by 2024 sales of AS03 adjuvant and divested brands as well
as competitive pressure and supply phasing for Cervarix. This was partially offset by
higher orders for MMR vaccines in the US due to measles
outbreaks.
|
|
|
|
|
|
General Medicines
|
2,488
|
(3%)
|
–%
|
Sales include contributions from both the Respiratory and Other
General Medicine portfolios. Sales were broadly stable in the
quarter at CER, with strong growth delivered across all regions
by Trelegy offset by decreases in Seretide/Advair,
other respiratory and Other General Medicine products. Sales in the
quarter at AER declined driven by exchange movements in a number of
International markets.
|
|
|
|
|
|
Respiratory
|
1,710
|
(1%)
|
1%
|
Sales
grew low single-digit in the quarter, with strong growth delivered
across all regions by Trelegy offset by declines in
Seretide/Advair and other
respiratory products. Declines in the quarter for Seretide/Advair and Flixotide/Flovent included the impacts
of adverse inventory movements in the US compared to Q1 2024.
Decreases in the quarter at AER were driven by exchange movements
in a number of International markets.
|
|
|
|
|
|
Trelegy
|
675
|
14%
|
15%
|
Trelegy sales continued to grow in the quarter, with strong
volume growth continued across all regions reflecting patient
demand, SITT class growth, and increased market share. Specifically
in the US, continued strong volume growth is partially offset by
price unfavourability resulting from channel mix and pricing
pressures and the impact of IRA Medicare Part D
redesign.
|
|
|
|
|
|
Other
General Medicines
|
778
|
(7%)
|
(3%)
|
Other
General Medicines sales decrease was driven by continued generic
competition across the portfolio. Decreases in the quarter at AER
were driven by exchange movements in a number of International
markets.
By Region
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
£m
|
AER
|
CER
|
|
US
|
3,752
|
5%
|
4%
|
Specialty
Medicines double-digit sales growth in the quarter was driven by
strong Oncology and HIV performance, and continued growth for
Nucala and Benlysta. The growth of Nucala and Benlysta was positively affected by the
impacts of channel inventory reductions that occurred in Q1
2024.
Vaccines
sales decreased in the quarter due to lower demand for both
Shingrix driven by the
continued challenge of activating harder-to reach consumers and
Arexvy due to a more
limited ACIP recommendation for RSV vaccination.
General
Medicines sales low single-digit growth in the quarter was
primarily driven by increased demand for Trelegy, with strong volume growth from
higher patient demand, partially offset by price unfavourability
resulting from continued channel pricing pressures and mix. Strong
growth in Trelegy sales was
partially offset by decreases across other general medicine
products.
US
performance in the quarter reflected the introduction of the IRA
Medicare Part D redesign, which adversely impacted a number of
products across Specialty Medicines, Vaccines and General
Medicines.
|
|
|
|
|
|
Europe
|
1,749
|
8%
|
11%
|
Specialty
Medicines sales grew by double-digits in the quarter due to
continued strong performance in Oncology, Benlysta and Nucala including the benefit from new
indication launches. Strong HIV growth continued in the quarter at
a mid-single digit percentage.
Vaccines
sales growth was driven by Shingrix new launch uptake in France
together with expanded public funding and higher private market
demand across several countries. Bexsero and Arexvy sales also grew strongly mainly
in Germany following recommendations.
General
Medicines sales decreased low single-digit in the quarter, with
double-digit growth for Trelegy and Anoro being more than offset by
decreases across other general medicine products.
|
|
|
|
|
|
International
|
2,015
|
(6%)
|
(2%)
|
Specialty
Medicines double-digit sales growth in the quarter was driven by
Nucala in respiratory,
Benlysta in immunology, and
Oncology. HIV delivered broadly stable sales in the
quarter.
Vaccines
sales decreased in the quarter with lower Shingrix sales due to a strong
comparator period which included rapid uptake from the national
immunisation programme in Australia together with lower current
quarter supply to our co-promotion partner in China. Established
Vaccines sales were also negatively impacted by 2024 sales of AS03
adjuvant and divested brands as well as Cervarix competitive pressure and
supply phasing.
General
Medicines sales decreased low single-digit in the quarter, with
double-digit growth for Trelegy and Anoro being more than offset by
decreases across other general medicine products.
|
|
|
Financial
performance
|
|
|
|
|
|
|
|
|
Total Results
|
Q1 2025
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Turnover
|
7,516
|
|
2
|
|
4
|
|
Cost of
sales
|
(1,937)
|
|
(2)
|
|
–
|
|
Selling,
general and administration
|
(2,070)
|
|
(1)
|
|
3
|
|
Research
and development
|
(1,462)
|
|
2
|
|
3
|
|
Royalty
income
|
180
|
|
19
|
|
21
|
|
Other
operating income/(expense)
|
(11)
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,216
|
|
49
|
|
50
|
|
Net
finance expense
|
(108)
|
|
(19)
|
|
(20)
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,108
|
|
56
|
|
57
|
|
|
|
|
|
|
|
|
Taxation
|
(336)
|
|
|
|
|
|
Tax rate %
|
15.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,772
|
|
64
|
|
66
|
|
Profit
attributable to non-controlling interests
|
148
|
|
|
|
|
|
Profit/(loss)
attributable to shareholders
|
1,624
|
|
|
|
|
|
|
1,772
|
|
64
|
|
66
|
|
|
|
|
|
|
|
|
Earnings
per share
|
39.7p
|
|
55
|
|
56
|
|
Financial Performance – Q1 2025 results unless otherwise
stated, growth % and commentary at CER.
|
|||||
|
|
|
Core results
Reconciliations
between Total results and Core results Q1 2025 and Q1 2024 are set
out on pages 19 and 20.
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Turnover
|
7,516
|
|
2
|
|
4
|
|
Cost of
sales
|
(1,726)
|
|
–
|
|
1
|
|
Selling,
general and administration
|
(2,060)
|
|
4
|
|
8
|
|
Research
and development
|
(1,377)
|
|
1
|
|
2
|
|
Royalty
income
|
180
|
|
19
|
|
21
|
|
|
|
|
|
|
|
|
Core
operating profit
|
2,533
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
Core
profit before taxation
|
2,432
|
|
5
|
|
6
|
|
Taxation
|
(434)
|
|
7
|
|
9
|
|
Tax rate %
|
17.8%
|
|
|
|
|
|
Core
profit after taxation
|
1,998
|
|
5
|
|
6
|
|
Core
profit attributable to non-controlling interests
|
162
|
|
|
|
|
|
Core
profit attributable to shareholders
|
1,836
|
|
|
|
|
|
|
1,998
|
|
5
|
|
6
|
|
Core
Earnings per share
|
44.9p
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Cost of
sales
|
Total
|
1,937
|
(2%)
|
–%
|
|
% of sales
|
25.8%
|
(1.0%)
|
(1.1%)
|
|
|
Core
|
1,726
|
–%
|
1%
|
|
|
% of sales
|
23.0%
|
(0.6%)
|
(0.7%)
|
|
Total
and Core cost of sales as a percentage of sales decreased in Q1
2025 primarily driven by mix benefits from growth in Specialty
Medicines, particularly Nucala and Benlysta, and regional margin mix from
higher US and Europe sales.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Selling,
general &
administration
|
Total
|
2,070
|
(1%)
|
3%
|
|
% of sales
|
27.5%
|
(0.8%)
|
(0.3%)
|
|
|
Core
|
2,060
|
4%
|
8%
|
|
|
% of sales
|
27.4%
|
0.5%
|
1.1%
|
|
Total
SG&A growth in the quarter was primarily driven by higher Core
SG&A spend, partly offset by lower Significant legal expenses.
Q1 2025 Core SG&A growth includes a 4 percentage point impact
driven by the Q1 2024 reversal of the legal provision related to
the Zejula royalty dispute,
following a successful appeal.
Core
SG&A growth in the quarter was driven by disciplined investment
to support the launch of new assets including depemokimab,
Penmenvy and Blenrep, and growth of key assets
including Ojjaara/Omjjara,
Nucala, and Shingrix, as well as investment behind
long-acting HIV medicines.
|
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
|
£m
|
AER
|
CER
|
|
Research
& development
|
Total
|
|
1,462
|
2%
|
3%
|
|
% of sales
|
|
19.5%
|
–%
|
(0.2%)
|
|
|
Core
|
|
1,377
|
1%
|
2%
|
|
|
% of sales
|
|
18.3%
|
(0.1%)
|
(0.3%)
|
|
In Q1
2025, Total and Core R&D investment increased in the quarter
driven by continued progression across the portfolio.
In
Specialty Medicines, investment increased to support late-stage
clinical development programmes for camlipixant, the long acting
TSLP asset, and bepirovirsen. HIV investment increased on
next-generation long-acting treatment and preventative medicines.
In Oncology, increased investment reflects acceleration in work on
antibody-drug-conjugates.
In
Vaccines, clinical trial programmes associated with the
pneumococcal MAPS and mRNA continued to drive
investment.
These
increases were partly offset by lower spend on depemokimab,
following filing for severe asthma and CRSwNP indications, and in
Blenrep (multiple myeloma)
and Zejula (endometrial
cancer) as studies progress to completion.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Royalty
income
|
Total
|
180
|
19%
|
21%
|
|
|
Core
|
180
|
19%
|
21%
|
The
increase in Total and Core royalty income in Q1 2025 primarily
reflected increases in Kesimpta and Biktarvy
royalties.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Other
operating
income/(expense)
|
Total
|
(11)
|
98%
|
98%
|
Q1 2025
other operating expense included a charge of £2 million (Q1
2024: £685 million) arising from the remeasurement of
contingent consideration liabilities (CCL) and the liabilities for
the Pfizer, Inc. (Pfizer) put option. The charge in the current
quarter primarily reflected discount unwind as well as changes to
sales forecasts, partly offset by favourable foreign exchange
movements. See page 21 for further details.
Other
net operating expense at £9m (Q1 2024: £152 million
income) reflected fair value movements on equity instruments,
partly offset by other net income. Q1 2024 included a fair value
gain of £57 million on the stake in Haleon plc.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Operating
profit
|
Total
|
2,216
|
49%
|
50%
|
|
|
% of sales
|
29.5%
|
9.2%
|
9.0%
|
|
|
Core
|
2,533
|
4%
|
5%
|
|
|
% of sales
|
33.7%
|
0.5%
|
0.3%
|
Total
operating profit margin was higher in the quarter mainly due to
lower CCL charges, partly offset by lower other net operating
income.
Core
operating profit growth in the quarter primarily reflected higher
turnover, favourable product mix and royalty income, partly offset
by increased investment in R&D, new asset launches and growth
assets. Growth was also offset by the Q1 2024 reversal of the
legal provision related to the Zejula royalty dispute, following a
successful appeal.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Net
finance expense
|
Total
|
108
|
(19%)
|
(20%)
|
|
|
Core
|
101
|
(23%)
|
(24%)
|
The
decrease in net finance costs in Q1 2025 was mainly driven by
higher income from net investment hedges, higher interest income on
cash and lower interest expense on tax.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Taxation
|
Total
|
336
|
23%
|
24%
|
|
|
Tax rate %
|
15.9%
|
|
|
|
|
Core
|
434
|
7%
|
9%
|
|
|
Tax rate %
|
17.8%
|
|
|
The
effective tax rate on Total results reflected the different tax
effects of the various Adjusting items included in Total
results.
The
effective tax rate on Core profits is broadly in line with
expectations for the year. Issues related to taxation are described
in Note 14, ‘Taxation’ in the Annual Report 2024. The
Group continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m
|
AER
|
CER
|
|
Non-controlling
interests ("NCIs")
|
Total
|
148
|
>100%
|
>100%
|
|
Core
|
162
|
5%
|
6%
|
|
The
increase in Total and Core NCIs in the quarter was primarily driven
by higher core profit allocations from ViiV Healthcare, and a lower
remeasurement loss on the CCL impacting Total NCIs.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£p
|
AER
|
CER
|
|
Earnings
per share
|
Total
|
39.7p
|
55%
|
56%
|
|
Core
|
44.9p
|
4%
|
5%
|
|
The
increase in the Q1 2025 Total EPS is driven by lower CCL
movements.
The
increase in the Core EPS in the quarter primarily reflected the
growth in Core operating profit as well as lower net finance costs,
partly offset by a higher effective taxation rate and higher
non-controlling interests.
Currency impact on results
The
results for Q1 2025 are based on average exchange rates,
principally $1.26/£1, €1.20/£1 and Yen193/£1.
The period-end exchange rates were $1.29/£1,
€1.20/£1 and Yen193/£1. Comparative exchange rates
are given on page 32.
|
|
|
|
|
|
|
|
|
Q1 2025
|
||
|
|
|
£m/£p
|
AER
|
CER
|
|
Turnover
|
|
7,516
|
2%
|
4%
|
|
Earnings
per share
|
Total
|
39.7p
|
55%
|
56%
|
|
Core
|
44.9p
|
4%
|
5%
|
|
In Q1
2025, the adverse currency impact primarily reflected the
strengthening of Sterling against the Euro, Yen and emerging market
currencies. Exchange losses on the settlement of intercompany
transactions in Q1 2024 resulted in a favourable impact of three
percentage points on Total EPS and two percentage points on Core
EPS growth at AER.
|
|
|
Cash generation
|
|
|
|
|
|
|
Cash flow
|
|||
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Cash
generated from operations (£m)
|
1,301
|
|
1,126
|
|
Total
net cash inflow/(outflow) from operating activities
(£m)
|
1,145
|
|
958
|
|
Free
cash inflow/(outflow)* (£m)
|
697
|
|
289
|
|
Free
cash flow growth (%)
|
>100%
|
|
>100%
|
|
Free
cash flow conversion* (%)
|
43%
|
|
28%
|
|
Total
net debt** (£m)
|
13,947
|
|
14,961
|
|
|
|
|
*
|
Free cash flow and free cash flow conversion are
defined on page 44. Free cash flow is analysed on page
35.
|
|
**
|
Net debt is analysed on pages 34 and
35.
|
Q1 2025
Cash
generated from operations for the quarter was £1,301 million
(Q1 2024: £1,126 million). The increase primarily
reflected higher operating profit and a favourable timing impact
from higher returns and rebates in comparison to lower returns and
rebates in Q1 2024 including the impact of the removal of the AMP
cap. This was partly offset by an adverse movement in receivables
driven by higher Arexvy and
Shingrix collections in Q1
2024.
Total
contingent consideration cash payments in the quarter were
£341 million (Q1 2024: £309 million).
£338 million (Q1 2024: £306 million) of
these were recognised in cash flows from operating activities,
including cash payments made to Shionogi & Co. Ltd (Shionogi)
of £331 million (Q1 2024:
£300 million).
Free
cash inflow was £697 million for the quarter (Q1 2024:
£289 million). The increase was primarily driven by
higher cash generated from operations, lower capital expenditure on
intangible assets and property, plant and equipment, higher
proceeds from the sale of intangible assets, and lower dividends
paid to non-controlling interests.
Total Net debt
At 31
March 2025, net debt was £13,947 million, compared with
£13,095 million at 31 December 2024, comprising gross debt of
£18,432 million and cash and liquid investments of £4,485
million. See net debt information on pages 34 and 35.
Net
debt increased by £852 million primarily due to the net
acquisition costs of IDRx, Inc. (IDRx) and Cellphenomics GmbH
totalling £800 million, dividends paid to shareholders of
£612 million, and shares purchased as part of the 2025 share
buyback programme of £247 million. This was partly offset by
free cash inflow of £697 million and exchange gain on net debt
of £187 million.
At 31
March 2025, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £1,958
million and £2,192 million repayable in the subsequent
year.
Contents
|
|
|
|
|
Page
|
|
Q1 2025
pipeline highlights
|
13
|
|
Responsible
business
|
15
|
|
Total
and Core results
|
17
|
|
Income
statement
|
22
|
|
Statement
of comprehensive income
|
23
|
|
Balance
sheet
|
24
|
|
Statement
of changes in equity
|
25
|
|
Cash
flow statement
|
26
|
|
Sales
tables
|
27
|
|
Segment
information
|
29
|
|
Legal
matters
|
30
|
|
Returns
to shareholders
|
31
|
|
Additional
information
|
32
|
|
R&D
commentary
|
36
|
|
Reporting
definitions
|
44
|
|
Guidance
and outlooks, assumptions and cautionary statements
|
46
|
|
Independent
Auditor's review report to GSK plc
|
48
|
|
Glossary
|
50
|
|
|
|
Contacts
|
|
|
|
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at www.gsk.com.
|
|
|
|
|
|
|
GSK enquiries:
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
7780 494750
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Investor
Relations
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
|||
|
|
|||
|
Registered Office:
79 New
Oxford Street
London,
WC1A
1DG
|
|||
|
|
|
Q1 2025 pipeline highlights (since
5 February 2025)
|
|
|
|
|
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory actions
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (UK)
|
|
Blujepa (gepotidacin)
|
EAGLE-2/3
(uncomplicated urinary tract infection)
|
Regulatory
approval (US)
|
|
|
Arexvy
|
RSV,
adults aged 50-59 years at increased risk
|
ACIP
recommendation (US)
|
|
|
Penmenvy (MenABCWY (gen 1) vaccine)
|
Meningococcal
ABCWY
|
Regulatory
approval (US)
|
|
|
Penmenvy (MenABCWY (gen 1) vaccine)
|
Meningococcal
ABCWY
|
ACIP
recommendation (US)
|
|
|
Regulatory submissions or acceptances
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps
|
Regulatory
acceptance
(US)
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
acceptance
(US)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
acceptance (CN, EU)
|
|
|
Phase III data readouts or other significant events
|
Zejula
|
ZEAL-1L
(1L maintenance non-small cell lung cancer)
|
Phase
III data readout
|
|
|
|
|
|
|
|
|
|
|
|
|
Anticipated pipeline milestones
|
||||
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1 2025
|
depemokimab
|
AGILE
(severe asthma)
|
Phase
III data readout
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission
(US,
EU)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (US)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (JP)
|
|
|
cobolimab
|
COSTAR
(non-small cell lung cancer)
|
Phase
III data readout
|
|
|
Shingrix
|
Shingles,
adults aged 18+ years at increased risk
|
Regulatory
decision (CN)
|
|
|
Shingrix
|
Shingles,
liquid formulation
|
Regulatory
decision (US)
|
|
|
H2 2025
|
camlipixant
|
CALM-1
(refractory chronic cough)
|
Phase
III data read out*
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
decision (US)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision (US)
|
|
|
depemokimab
|
NIMBLE
(severe asthma)
|
Phase
III data readout
|
|
|
latozinemab
|
INFRONT-3
(frontotemporal dementia)
|
Phase
III data read out
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision (US)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission (CN, JP)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Phase
III data readout
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
submission (EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (US, EU)
|
|
|
Blenrep
|
DREAMM-8
(2L + multiple myeloma)
|
Regulatory
submission (CN)
|
|
|
cobolimab
|
COSTAR,
(2L non-small cell lung cancer)
|
Regulatory
submission
(US,
EU)
|
*CALM-1 results will be disclosed together with
CALM-2
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H2 2025
|
Arexvy
|
RSV,
adults aged 60+ years
|
Phase
III read out (CN)
|
|
Arexvy
|
RSV,
adults aged 18-49 years at increased risk, 18+
immunocompromised
|
Regulatory
submission
(US,
EU, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Phase
III data read out
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
submission (US)
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
decision (US)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Phase
III data readout
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
submission (US)
|
|
|
2026
|
camlipixant
|
CALM-2
(refractory chronic cough)
|
Phase
III data read out
|
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Regulatory
submission (US, EU, JP)
|
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Phase
III data read out
|
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
latozinemab
|
INFRONT-3
(frontotemporal dementia)
|
Regulatory
submission
(US,
EU)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (EU, CN)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
decision (EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (CN)
|
|
|
cobolimab
|
COSTAR
(2L non-small cell lung cancer)
|
Regulatory
decision (US, EU)
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Phase
II (pivotal) data read out
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Phase
II (pivotal) data read out
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Regulatory
submission (US)
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Regulatory
decision (US)
|
|
|
Arexvy
|
RSV,
adults aged 60+ years
|
Regulatory
submission (CN)
|
|
|
Arexvy
|
RSV,
adults aged 18-49 years at increased risk and 18+
immunocompromised
|
Regulatory
decision
(US,
EU, JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Phase
III data read out
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Regulatory
decision (US, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
submission (US)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
decision (US)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
decision (US)
|
|
|
|
|
|
|
|
Refer
to pages 36 to 43 for further details on several key medicines and
vaccines in development by therapy area.
|
||||
Trust: progress on our six priority
areas for responsible business
Building Trust by operating responsibly is integral to GSK’s
strategy and culture. This will support growth and returns to
shareholders, reduce risk, and help GSK’s people thrive while
delivering sustainable health impact at scale. The Company has
identified six Responsible Business focus areas that address what
is most material to GSK’s business and the issues that matter
the most to its stakeholders. Highlights below include activity
since Q4 2024 results. For more details on annual updates,
please see GSK's Responsible
Business Performance Report 2024(1).
Access
Commitment:
to make GSK’s vaccines and
medicines available at value-based prices that are sustainable for
the business and implement access strategies that increase the use
of GSK’s vaccines and medicines to treat and protect
underserved people.
Progress
since Q4 2024:
|
|
|
|
●
|
Burundi
has become the tenth country to roll out RTS,S (Mosquirix),
GSK’s world first malaria vaccine, as part of the routine
immunisation schedule. More information can be found here(2).
|
|
●
|
Performance
metrics related to access are updated annually with related details
in GSK's
Responsible Business Performance Report 2024(1) on page
11.
|
Global health and health security
Commitment:
develop novel products and technologies to treat and prevent
priority diseases, including pandemic threats.
Progress
since Q4 2024:
|
|
|
|
●
|
A phase
II trial evaluating a pulmonary tuberculosis drug combination has
commenced with the first patient dosed as part of a partnership
between GSK and BioVersys which is aimed at researching and
developing novel antibacterial products for serious
life-threatening infections caused by multidrug-resistant bacteria.
More information can be found here(3).
|
|
●
|
GSK and
Chugai Pharmaceutical have signed a collaboration agreement for the
development of an anti-dengue virus antibody, AID351. Under this
agreement, GSK will perform activities and evaluate potential
funding for the initiation of the related clinical studies. More
information can be found here(4).
|
|
●
|
Performance
metrics related to global health and health security are updated
annually with related details in GSK's
Responsible Business Performance Report
2024(1) on page
16.
|
Environment
Commitment:
committed to a net zero, nature-positive, healthier planet with
ambitious goals set for 2030 and 2045.
Progress
since Q4 2024:
|
|
|
|
●
|
GSK was
featured in CDP’s ‘A List’ for Climate Change and
Water Security, and scored a B for Forests in their most recent
rankings.
|
|
●
|
GSK and
WWF announced a new 5-year partnership focused on building business
resilience and protecting and restoring freshwater ecosystems, both
within GSK’s operations and in its supply chain in
water-stressed basins in India and Pakistan.
|
|
●
|
GSK
continued to make progress on transitioning to renewable energy,
co-leading a renewable power programme with suppliers in China
through the Sustainable Markets Initiative. Through this
partnership, GSK and other industry peers are expected to
contribute an estimated 225 GWh of renewable energy to the grid
annually. GSK also signed a new deal as part of the Energize
programme which involved GSK, industry peers and suppliers across
Europe, and is set to contribute approximately 245 GWh of new
renewable energy annually to the grid.
|
|
●
|
Performance
metrics related to environment are updated annually with related
details in GSK's Responsible Business Performance
Report 2024(1) on page
19.
|
Inclusion
Commitment:
meet patients’ needs with research that includes those
impacted by the disease under study, attract and retain the best
talent regardless of background, and support all GSK people to
thrive.
|
|
|
|
●
|
Performance
metrics related to inclusion are updated annually with related
details in GSK's Responsible Business Performance
Report 2024(1) on page
27.
|
Ethical standards
Commitment:
promote ethical behaviour across GSK’s business by supporting
its employees to do the right thing and working with suppliers that
share GSK’s standards and operate responsibly.
|
|
|
|
●
|
Performance
metrics related to ethical standards are updated annually with
related details in GSK's Responsible Business Performance
Report 2024(1) on page
29.
|
Product governance
Commitment:
maintain robust quality and safety processes and responsibly use
data and new technologies.
|
|
|
|
●
|
Performance
metrics related to product governance are updated annually with
related details in GSK's Responsible Business Performance
Report 2024(1)
on page 34.
|
Responsible Business rating performance
Detailed
below is how GSK performs in key Responsible Business
ratings.
|
|
|
|
|
|
External benchmark
|
Current
score/ranking
|
Previous
score/ranking
|
Comments
|
|
S&P
Global’s Corporate Sustainability Assessment
|
78
|
80
|
Current
score updated September 2024
|
|
Access
to Medicines Index
|
3.72
|
4.06
|
Second
in the Index, updated bi-annually, current results from November
2024
|
|
Antimicrobial
resistance benchmark
|
84%
|
86%
|
Led the
benchmark since its inception in 2018; Current ranking updated
November 2021
|
|
CDP
Climate Change
|
A
|
A-
|
Updated
annually, current scores updated February 2025 (for supplier
engagement, March 2023)
|
|
CDP
Water Security
|
A
|
A-
|
|
|
CDP
Forests (palm oil)
|
B
|
B
|
|
|
CDP
Forests (timber)
|
B
|
B
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
|
|
Sustainalytics
|
15.0
|
15.4
|
1st
percentile in pharma subindustry group; lower score represents
lower risk. Current score as at December 2024
|
|
MSCI
|
AA
|
AA
|
Last
rating action date: September 2023
|
|
Moody’s
ESG solutions
|
62
|
61
|
Current
score updated August 2023
|
|
ISS
Corporate Rating
|
B+
|
B+
|
Current
score updated October 2024
|
|
FTSE4Good
|
Member
|
Member
|
Member
since 2004, latest review in June 2024
|
|
ShareAction’s
Workforce Disclosure Initiative
|
79%
|
77%
|
Current
score updated January 2024
|
Footnotes:
|
|
|
|
(1)
|
https://www.gsk.com/media/11863/responsible-business-performance-report-2024.pdf
|
|
(2)
|
https://www.gavi.org/news/media-room/burundi-introduces-malaria-vaccine-routine-immunization
|
|
(3)
|
https://ir.bioversys.com/news/first-ever-patient-dosed-with-alpibectir-ethionamide-in-combination-with-first-line-tb-drugs-in-a-14-day/26cbb071-386b-400b-a07b-636e588777d2
|
|
(4)
|
https://www.chugai-pharm.co.jp/english/news/detail/20250130170001_1126.html
|
|
(5)
|
https://www.savethechildren.net/ethiopia/news/innovations-breaking-barriers-childrens-immunisation-nigeria-and-ethiopia-win-major
|
Total and Core
results
Total
reported results represent the Group’s overall
performance.
GSK
uses a number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. Core results are
defined below and other non-IFRS measures are defined on pages 44
and 45.
GSK
believes that Core results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Core
results exclude the following items in relation to our operations
from Total results, together with the tax effects of all of these
items:
|
|
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; Significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items including amounts reclassified from
the foreign currency translation reserve to the income statement
upon the liquidation of a subsidiary where the amount exceeds
£25 million
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from operations are retained within both Total
and Core results.
As Core
results include the benefits of Major restructuring programmes but
exclude significant costs (such as Significant legal, major
restructuring and transaction items) they should not be regarded as
a complete picture of the Group’s financial performance,
which is presented in Total results. The exclusion of other
Adjusting items may result in Core earnings being materially higher
or lower than Total earnings. In particular, when significant
impairments, restructuring charges and legal costs are excluded,
Core earnings will be higher than Total earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Core results, providing further information on
the key Adjusting items, are set out on pages 19 and
20.
GSK
provides earnings guidance to the investor community on the basis
of Core results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 85% of the Total
earnings and 83% of the Core earnings of ViiV Healthcare for
2024.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in the three months
ended 31 March 2025 were £331 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 89 and 90 of the Annual Report
2024.
The
reconciliations between Total results and Core results for Q1 2025
and Q1 2024 are set out below.
Three months ended 31 March 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,516
|
|
|
|
|
|
|
|
|
|
|
|
7,516
|
|
Cost of
sales
|
(1,937)
|
|
198
|
|
|
|
11
|
|
|
|
2
|
|
(1,726)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,579
|
|
198
|
|
|
|
11
|
|
|
|
2
|
|
5,790
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,070)
|
|
|
|
|
|
8
|
|
8
|
|
(6)
|
|
(2,060)
|
|
Research
and development
|
(1,462)
|
|
21
|
|
64
|
|
1
|
|
|
|
(1)
|
|
(1,377)
|
|
Royalty
income
|
180
|
|
|
|
|
|
|
|
|
|
|
|
180
|
|
Other
operating income/(expense)
|
(11)
|
|
|
|
|
|
|
|
2
|
|
9
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,216
|
|
219
|
|
64
|
|
20
|
|
10
|
|
4
|
|
2,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(108)
|
|
|
|
|
|
|
|
|
|
7
|
|
(101)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,108
|
|
219
|
|
64
|
|
20
|
|
10
|
|
11
|
|
2,432
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(336)
|
|
(51)
|
|
(16)
|
|
(5)
|
|
(30)
|
|
4
|
|
(434)
|
|
Tax rate %
|
15.9%
|
|
|
|
|
|
|
|
|
|
|
|
17.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,772
|
|
168
|
|
48
|
|
15
|
|
(20)
|
|
15
|
|
1,998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
148
|
|
|
|
|
|
|
|
14
|
|
|
|
162
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss)
attributable to shareholders
|
1,624
|
|
168
|
|
48
|
|
15
|
|
(34)
|
|
15
|
|
1,836
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,772
|
|
168
|
|
48
|
|
15
|
|
(20)
|
|
15
|
|
1,998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
39.7p
|
|
4.1p
|
|
1.2p
|
|
0.4p
|
|
(0.9p)
|
|
0.4p
|
|
44.9p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,088
|
|
|
|
|
|
|
|
|
|
|
|
4,088
|
Three months ended 31 March 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,363
|
|
|
|
|
|
|
|
|
|
|
|
7,363
|
|
Cost of
sales
|
(1,970)
|
|
182
|
|
|
|
33
|
|
19
|
|
3
|
|
(1,733)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,393
|
|
182
|
|
|
|
33
|
|
19
|
|
3
|
|
5,630
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,087)
|
|
|
|
|
|
17
|
|
|
|
91
|
|
(1,979)
|
|
Research
and development
|
(1,434)
|
|
14
|
|
54
|
|
7
|
|
|
|
|
|
(1,359)
|
|
Royalty
income
|
151
|
|
|
|
|
|
|
|
|
|
|
|
151
|
|
Other
operating income/(expense)
|
(533)
|
|
|
|
|
|
|
|
685
|
|
(152)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,490
|
|
196
|
|
54
|
|
57
|
|
704
|
|
(58)
|
|
2,443
|
|
Net
finance expense
|
(134)
|
|
|
|
|
|
|
|
|
|
2
|
|
(132)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Profit before taxation
|
1,355
|
|
196
|
|
54
|
|
57
|
|
704
|
|
(56)
|
|
2,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(274)
|
|
(41)
|
|
(14)
|
|
(13)
|
|
(76)
|
|
14
|
|
(404)
|
|
Tax rate %
|
20.2%
|
|
|
|
|
|
|
|
|
|
|
|
17.5%
|
|
Profit after taxation
|
1,081
|
|
155
|
|
40
|
|
44
|
|
628
|
|
(42)
|
|
1,906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
35
|
|
|
|
|
|
|
|
119
|
|
|
|
154
|
|
Profit
attributable to shareholders
|
1,046
|
|
155
|
|
40
|
|
44
|
|
509
|
|
(42)
|
|
1,752
|
|
|
1,081
|
|
155
|
|
40
|
|
44
|
|
628
|
|
(42)
|
|
1,906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
25.7p
|
|
3.8p
|
|
1.0p
|
|
1.1p
|
|
12.5p
|
|
(1.0p)
|
|
43.1p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares (millions)
|
4,069
|
|
|
|
|
|
|
|
|
|
|
|
4,069
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusting items Q1
2025
Major restructuring and integration
Total
Major restructuring charges incurred in Q1 2025 were £20
million (Q1 2024: £57 million), analysed as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
|
Q1
2024
|
||||||||
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
6
|
|
12
|
|
18
|
|
28
|
|
8
|
|
36
|
|
Significant
acquisitions
|
1
|
|
–
|
|
1
|
|
19
|
|
–
|
|
19
|
|
Legacy
programmes
|
1
|
|
–
|
|
1
|
|
2
|
|
–
|
|
2
|
|
|
8
|
|
12
|
|
20
|
|
49
|
|
8
|
|
57
|
The
Separation restructuring programme incurred cash charges of £6
million primarily from restructuring of some commercial and
administrative functions as well as Global Supply Chain. The
non-cash charges of £12 million primarily reflected the write
down of assets in manufacturing locations.
Costs
of significant acquisitions relate to integration costs of
Affinivax Inc. (Affinivax) which was acquired in Q3 2022, BELLUS
Health Inc. acquired in Q2 2023, Aiolos Bio, Inc. (Aiolos) acquired
in Q1 2024 and IDRx acquired in Q1 2025.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £10 million (Q1 2024:
£704 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities, the liabilities for the Pfizer put option, and Pfizer
and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including Shionogi preferential dividends)
|
39
|
|
586
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(60)
|
|
66
|
|
Contingent
consideration on former Novartis Vaccines business
|
52
|
|
28
|
|
Contingent
consideration on acquisition of Affinivax
|
(33)
|
|
5
|
|
Other
contingent consideration
|
4
|
|
–
|
|
Other
adjustments
|
8
|
|
19
|
|
|
|
|
|
|
Total
transaction-related charges
|
10
|
|
704
|
The
£39 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi driven by the unwind of the discount for £114 million
partly offset by updated exchange rates and net other
remeasurements of £75 million. The £586 million charge in
Q1 2024 primarily reflected updated sales forecasts due to improved
longer term HIV prospects, as well as exchange movements and the
unwind of the discount. The £60 million credit relating to the
ViiV Healthcare put option and Pfizer preferential dividends
represented a decrease in the valuation of the put option primarily
as a result of updated exchange rates and lower cash balances. An
explanation of the accounting for the non-controlling interests in
ViiV Healthcare is set out on page 18.
There
was a £52 million charge in the quarter relating to the
contingent consideration on the former Novartis Vaccines business
primarily related to changes to future sales forecasts and the
unwind of the discount.
The
£33 million credit relating to the contingent consideration on
the acquisition of Affinivax primarily related to updated milestone
payment dates partly offset by the unwind of the
discount.
Significant legal charges, Divestments, and other
items
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
Divestments
and other items included other net income, including fair value
movements on equity investments and royalty income.
|
|
|
Financial
information
|
|
Income
statement
|
|
|
|
|
|
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
|
|
|
|
|
TURNOVER
|
7,516
|
|
7,363
|
|
|
|
|
|
|
Cost of
sales
|
(1,937)
|
|
(1,970)
|
|
Gross
profit
|
5,579
|
|
5,393
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,070)
|
|
(2,087)
|
|
Research
and development
|
(1,462)
|
|
(1,434)
|
|
Royalty
income
|
180
|
|
151
|
|
Other
operating income/(expense)
|
(11)
|
|
(533)
|
|
|
|
|
|
|
OPERATING PROFIT
|
2,216
|
|
1,490
|
|
|
|
|
|
|
Finance
income
|
54
|
|
32
|
|
Finance
expense
|
(162)
|
|
(166)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
–
|
|
(1)
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
2,108
|
|
1,355
|
|
|
|
|
|
|
Taxation
|
(336)
|
|
(274)
|
|
Tax rate %
|
15.9%
|
|
20.2%
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
1,772
|
|
1,081
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
148
|
|
35
|
|
Profit
attributable to shareholders
|
1,624
|
|
1,046
|
|
|
1,772
|
|
1,081
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
39.7p
|
|
25.7p
|
|
|
|
|
|
|
Diluted
earnings per share
|
39.3p
|
|
25.4p
|
|
|
|
|
|
|
|
|
Statement of comprehensive
income
|
|
|
|
|
|
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
|
|
|
|
|
Total
profit for the period
|
1,772
|
|
1,081
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
138
|
|
(190)
|
|
Reclassification of
exchange movements on liquidation or disposal of overseas
subsidiaries and associates
|
(1)
|
|
–
|
|
Fair
value movements on cash flow hedges
|
(4)
|
|
–
|
|
Cost of
hedging
|
4
|
|
–
|
|
Reclassification
of cash flow hedges to income statement
|
(5)
|
|
2
|
|
|
|
|
|
|
|
132
|
|
(188)
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
(8)
|
|
3
|
|
Fair
value movements on equity investments
|
(121)
|
|
78
|
|
Tax on
fair value movements on equity investments
|
7
|
|
(15)
|
|
Fair
value movements on cash flow hedges
|
–
|
|
1
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
56
|
|
46
|
|
Tax on
remeasurement losses/(gains) on defined benefit plans
|
(14)
|
|
(10)
|
|
|
|
|
|
|
|
(80)
|
|
103
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
52
|
|
(85)
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
1,824
|
|
996
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
1,684
|
|
958
|
|
Non-controlling interests
|
140
|
|
38
|
|
|
|
|
|
|
|
1,824
|
|
996
|
|
|
|
Balance
sheet
|
|
|
|
|
|
|
|
31 March 2025
£m
|
|
31
December 2024
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
9,154
|
|
9,227
|
|
Right
of use assets
|
817
|
|
846
|
|
Goodwill
|
6,926
|
|
6,982
|
|
Other
intangible assets
|
16,258
|
|
15,515
|
|
Investments
in associates and joint ventures
|
99
|
|
96
|
|
Other
investments
|
933
|
|
1,100
|
|
Deferred
tax assets
|
6,410
|
|
6,757
|
|
Derivative
instruments
|
–
|
|
1
|
|
Other
non-current assets
|
2,023
|
|
1,942
|
|
|
|
|
|
|
Total non-current assets
|
42,620
|
|
42,466
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
6,000
|
|
5,669
|
|
Current
tax recoverable
|
442
|
|
489
|
|
Trade
and other receivables
|
7,059
|
|
6,836
|
|
Derivative
financial instruments
|
95
|
|
109
|
|
Liquid
investments
|
21
|
|
21
|
|
Cash
and cash equivalents
|
4,464
|
|
3,870
|
|
Assets
held for sale
|
4
|
|
3
|
|
|
|
|
|
|
Total current assets
|
18,085
|
|
16,997
|
|
|
|
|
|
|
TOTAL ASSETS
|
60,705
|
|
59,463
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(1,958)
|
|
(2,349)
|
|
Contingent
consideration liabilities
|
(1,175)
|
|
(1,172)
|
|
Trade
and other payables
|
(15,149)
|
|
(15,335)
|
|
Derivative
financial instruments
|
(81)
|
|
(192)
|
|
Current
tax payable
|
(628)
|
|
(703)
|
|
Short-term
provisions
|
(1,840)
|
|
(1,946)
|
|
|
|
|
|
|
Total current liabilities
|
(20,831)
|
|
(21,697)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(16,474)
|
|
(14,637)
|
|
Corporation
tax payable
|
(31)
|
|
–
|
|
Deferred
tax liabilities
|
(404)
|
|
(382)
|
|
Pensions
and other post-employment benefits
|
(1,870)
|
|
(1,864)
|
|
Derivative
financial instruments
|
(2)
|
|
–
|
|
Other
provisions
|
(555)
|
|
(589)
|
|
Contingent
consideration liabilities
|
(5,854)
|
|
(6,108)
|
|
Other
non-current liabilities
|
(1,030)
|
|
(1,100)
|
|
|
|
|
|
|
Total non-current liabilities
|
(26,220)
|
|
(24,680)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(47,051)
|
|
(46,377)
|
|
|
|
|
|
|
NET ASSETS
|
13,654
|
|
13,086
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,349
|
|
1,348
|
|
Share
premium account
|
3,484
|
|
3,473
|
|
Retained
earnings
|
8,307
|
|
7,796
|
|
Other
reserves
|
1,017
|
|
1,054
|
|
|
|
|
|
|
Shareholders’ equity
|
14,157
|
|
13,671
|
|
|
|
|
|
|
Non-controlling
interests
|
(503)
|
|
(585)
|
|
|
|
|
|
|
TOTAL EQUITY
|
13,654
|
|
13,086
|
|
|
|
Statement of changes in
equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2025
|
1,348
|
|
3,473
|
|
7,796
|
|
1,054
|
|
13,671
|
|
(585)
|
|
13,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,624
|
|
|
|
1,624
|
|
148
|
|
1,772
|
|
Other comprehensive income /(expense) for the period
|
|
|
|
|
172
|
|
(112)
|
|
60
|
|
(8)
|
|
52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense) for the period
|
|
|
|
|
1,796
|
|
(112)
|
|
1,684
|
|
140
|
|
1,824
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions to
non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(58)
|
|
(58)
|
|
Dividends
to shareholders
|
|
|
|
|
(612)
|
|
|
|
(612)
|
|
|
|
(612)
|
|
Shares
issued
|
1
|
|
11
|
|
|
|
|
|
12
|
|
|
|
12
|
|
Share
buyback programme:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
of treasury shares (1)
|
–
|
|
|
|
(701)
|
|
|
|
(701)
|
|
|
|
(701)
|
|
Write-down on
shares held by ESOP Trusts
|
|
|
|
|
(75)
|
|
75
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
103
|
|
|
|
103
|
|
|
|
103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 March 2025
|
1,349
|
|
3,484
|
|
8,307
|
|
1,017
|
|
14,157
|
|
(503)
|
|
13,654
|
(1) Includes shares committed to repurchase under irrevocable
contracts and repurchases subject to settlement at the end of the
period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2024
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,046
|
|
–
|
|
1,046
|
|
35
|
|
1,081
|
|
Other comprehensive income/(expense) for the period
|
|
|
|
|
(151)
|
|
63
|
|
(88)
|
|
3
|
|
(85)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense) for the period
|
|
|
|
|
895
|
|
63
|
|
958
|
|
38
|
|
996
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(97)
|
|
(97)
|
|
Dividends
to shareholders
|
|
|
|
|
(568)
|
|
|
|
(568)
|
|
|
|
(568)
|
|
Realised after tax
losses on disposal or liquidation of equity
investments
|
|
|
|
|
(47)
|
|
47
|
|
|
|
|
|
–
|
|
Share
of associates and joint ventures realised profit/(loss) on disposal
of equity investments
|
|
|
|
|
15
|
|
(15)
|
|
|
|
|
|
–
|
|
Shares
issued
|
|
|
18
|
|
|
|
|
|
18
|
|
|
|
18
|
|
Write-down
of shares held by ESOP Trusts
|
|
|
|
|
(141)
|
|
141
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
457
|
|
(459)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
85
|
|
|
|
85
|
|
|
|
85
|
|
At 31
March 2024
|
1,348
|
|
3,471
|
|
7,935
|
|
1,086
|
|
13,840
|
|
(611)
|
|
13,229
|
|
|
|
Cash flow statement three
months ended 31 March 2025
|
|
|
|
|
|
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Profit after tax
|
1,772
|
|
1,081
|
|
Tax on
profits
|
336
|
|
274
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
–
|
|
1
|
|
Net
finance expense
|
108
|
|
134
|
|
Depreciation,
amortisation and other adjusting items
|
823
|
|
549
|
|
(Increase)/decrease
in working capital
|
(788)
|
|
(311)
|
|
Contingent
consideration paid
|
(338)
|
|
(306)
|
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
(612)
|
|
(296)
|
|
Cash generated from operations
|
1,301
|
|
1,126
|
|
Taxation
paid
|
(156)
|
|
(168)
|
|
Total net cash inflow/(outflow) from operating
activities
|
1,145
|
|
958
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase
of property, plant and equipment
|
(208)
|
|
(248)
|
|
Proceeds
from sale of property, plant and equipment
|
1
|
|
1
|
|
Purchase
of intangible assets
|
(240)
|
|
(315)
|
|
Proceeds
from sale of intangible assets
|
76
|
|
27
|
|
Purchase
of equity investments
|
(22)
|
|
(18)
|
|
Proceeds
from sale of equity investments
|
–
|
|
1,055
|
|
Purchase
of businesses, net of cash acquired
|
(800)
|
|
(719)
|
|
Contingent
consideration paid
|
(3)
|
|
(3)
|
|
Disposal
of businesses
|
(1)
|
|
(3)
|
|
Interest
received
|
53
|
|
37
|
|
(Increase)/decrease
in liquid investments
|
–
|
|
22
|
|
Dividend
and distributions from investments
|
–
|
|
15
|
|
Total net cash inflow/(outflow) from investing
activities
|
(1,144)
|
|
(149)
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
Issue
of share capital
|
12
|
|
18
|
|
Issue
of long-term notes
|
2,018
|
|
–
|
|
Net
increase/(decrease) in short-term loans
|
–
|
|
(323)
|
|
Increase
in other short-term loans
|
59
|
|
–
|
|
Repayment
of other short-term loans
|
(159)
|
|
–
|
|
Repayment
of lease liabilities
|
(57)
|
|
(57)
|
|
Interest
paid
|
(69)
|
|
(71)
|
|
Dividends
paid to shareholders
|
(612)
|
|
(568)
|
|
Purchase
of treasury shares
|
(247)
|
|
–
|
|
Distribution
to non-controlling interests
|
(58)
|
|
(97)
|
|
Other
financing items
|
(29)
|
|
38
|
|
Total net cash inflow/(outflow) from financing
activities
|
858
|
|
(1,060)
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
859
|
|
(251)
|
|
Cash
and bank overdrafts at beginning of the period
|
3,403
|
|
2,858
|
|
Exchange
adjustments
|
(11)
|
|
(19)
|
|
Increase/(decrease)
in cash and bank overdrafts in the period
|
859
|
|
(251)
|
|
Cash and bank overdrafts at end of the period
|
4,251
|
|
2,588
|
|
Cash
and bank overdrafts at end of period comprise:
|
|
|
|
|
Cash and cash equivalents
|
4,464
|
|
2,790
|
|
Overdrafts
|
(213)
|
|
(202)
|
|
|
4,251
|
|
2,588
|
Specialty Medicines turnover – three months ended 31 March
2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
HIV
|
1,714
|
6
|
7
|
|
1,133
|
10
|
9
|
|
373
|
2
|
5
|
|
208
|
(5)
|
–
|
|
Dolutegravir
products
|
1,288
|
(1)
|
–
|
|
773
|
–
|
–
|
|
323
|
–
|
2
|
|
192
|
(8)
|
(4)
|
|
Tivicay
|
314
|
(11)
|
(10)
|
|
174
|
(6)
|
(6)
|
|
58
|
(9)
|
(8)
|
|
82
|
(21)
|
(18)
|
|
Triumeq
|
246
|
(21)
|
(20)
|
|
168
|
(20)
|
(21)
|
|
45
|
(24)
|
(22)
|
|
33
|
(18)
|
(10)
|
|
Juluca
|
158
|
1
|
1
|
|
124
|
2
|
1
|
|
31
|
(3)
|
–
|
|
3
|
–
|
–
|
|
Dovato
|
570
|
18
|
19
|
|
307
|
21
|
21
|
|
189
|
12
|
15
|
|
74
|
21
|
25
|
|
Cabenuva
|
294
|
38
|
38
|
|
240
|
40
|
40
|
|
46
|
31
|
37
|
|
8
|
14
|
14
|
|
Apretude
|
89
|
65
|
63
|
|
87
|
61
|
61
|
|
–
|
–
|
–
|
|
2
|
–
|
–
|
|
Rukobia
|
38
|
15
|
15
|
|
32
|
3
|
3
|
|
3
|
50
|
–
|
|
3
|
>100
|
>100
|
|
Other
|
5
|
(44)
|
(22)
|
|
1
|
(67)
|
(100)
|
|
1
|
(67)
|
–
|
|
3
|
–
|
33
|
|
Respiratory,
Immunology and Inflammation
|
804
|
26
|
28
|
|
497
|
31
|
31
|
|
150
|
14
|
17
|
|
157
|
25
|
31
|
|
Nucala
|
444
|
19
|
21
|
|
213
|
18
|
18
|
|
125
|
15
|
18
|
|
106
|
25
|
32
|
|
Benlysta
|
359
|
38
|
39
|
|
284
|
43
|
43
|
|
31
|
15
|
19
|
|
44
|
26
|
31
|
|
Other
|
1
|
(51)
|
(51)
|
|
–
|
–
|
–
|
|
(6)
|
(50)
|
(50)
|
|
7
|
17
|
17
|
|
Oncology
|
415
|
52
|
53
|
|
292
|
57
|
56
|
|
96
|
28
|
31
|
|
27
|
>100
|
>100
|
|
Jemperli
|
174
|
>100
|
>100
|
|
137
|
>100
|
>100
|
|
27
|
93
|
100
|
|
10
|
>100
|
>100
|
|
Zejula
|
131
|
(7)
|
(5)
|
|
62
|
(14)
|
(15)
|
|
56
|
(3)
|
(2)
|
|
13
|
18
|
45
|
|
Blenrep
|
–
|
–
|
–
|
|
–
|
–
|
–
|
|
–
|
–
|
–
|
|
–
|
–
|
–
|
|
Ojjaara/Omjjara
|
112
|
>100
|
>100
|
|
94
|
88
|
86
|
|
14
|
>100
|
>100
|
|
4
|
>100
|
>100
|
|
Other
|
(2)
|
>(100)
|
–
|
|
(1)
|
–
|
–
|
|
(1)
|
–
|
–
|
|
–
|
–
|
–
|
|
Specialty Medicines
|
2,933
|
16
|
17
|
|
1,922
|
21
|
20
|
|
619
|
8
|
12
|
|
392
|
10
|
16
|
Vaccines turnover – three months ended 31 March
2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Shingles
|
867
|
(8)
|
(7)
|
|
372
|
(21)
|
(21)
|
|
291
|
27
|
31
|
|
204
|
(17)
|
(13)
|
|
Shingrix
|
867
|
(8)
|
(7)
|
|
372
|
(21)
|
(21)
|
|
291
|
27
|
31
|
|
204
|
(17)
|
(13)
|
|
Meningitis
|
350
|
17
|
20
|
|
122
|
1
|
–
|
|
138
|
37
|
41
|
|
90
|
17
|
26
|
|
Bexsero
|
251
|
16
|
20
|
|
70
|
(3)
|
(3)
|
|
135
|
38
|
42
|
|
46
|
(2)
|
9
|
|
Menveo
|
89
|
11
|
13
|
|
52
|
6
|
4
|
|
2
|
–
|
–
|
|
35
|
21
|
28
|
|
Other
|
10
|
>100
|
>100
|
|
–
|
–
|
–
|
|
1
|
–
|
–
|
|
9
|
>100
|
>100
|
|
RSV
|
78
|
(57)
|
(57)
|
|
55
|
(64)
|
(64)
|
|
19
|
>100
|
>100
|
|
4
|
(85)
|
(85)
|
|
Arexvy
|
78
|
(57)
|
(57)
|
|
55
|
(64)
|
(64)
|
|
19
|
>100
|
>100
|
|
4
|
(85)
|
(85)
|
|
Influenza
|
1
|
(92)
|
(92)
|
|
(4)
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
5
|
(55)
|
(55)
|
|
Fluarix, FluLaval
|
1
|
(92)
|
(92)
|
|
(4)
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
5
|
(55)
|
(55)
|
|
Established
Vaccines
|
799
|
(5)
|
(3)
|
|
343
|
4
|
3
|
|
167
|
(6)
|
(3)
|
|
289
|
(12)
|
(9)
|
|
Boostrix
|
151
|
9
|
11
|
|
88
|
4
|
4
|
|
35
|
6
|
9
|
|
28
|
40
|
45
|
|
Cervarix
|
11
|
(66)
|
(62)
|
|
–
|
–
|
–
|
|
2
|
(50)
|
(50)
|
|
9
|
(68)
|
(64)
|
|
Hepatitis
|
170
|
(3)
|
(2)
|
|
92
|
1
|
1
|
|
46
|
(10)
|
(6)
|
|
32
|
(3)
|
(3)
|
|
Infanrix, Pediarix
|
145
|
–
|
1
|
|
82
|
(6)
|
(6)
|
|
28
|
(10)
|
(6)
|
|
35
|
30
|
33
|
|
Priorix, Priorix Tetra,Varilrix
|
96
|
23
|
26
|
|
23
|
>100
|
>100
|
|
29
|
–
|
–
|
|
44
|
2
|
7
|
|
Rotarix
|
141
|
(8)
|
(6)
|
|
54
|
(5)
|
(5)
|
|
32
|
10
|
14
|
|
55
|
(19)
|
(15)
|
|
Synflorix
|
51
|
13
|
18
|
|
–
|
–
|
–
|
|
1
|
(50)
|
(50)
|
|
50
|
16
|
21
|
|
Other
|
34
|
(52)
|
(52)
|
|
4
|
(20)
|
(40)
|
|
(6)
|
>(100)
|
>(100)
|
|
36
|
(46)
|
(45)
|
|
Vaccines
|
2,095
|
(8)
|
(6)
|
|
888
|
(18)
|
(18)
|
|
615
|
21
|
24
|
|
592
|
(14)
|
(10)
|
General Medicines turnover – three months ended 31 March
2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Respiratory
|
1,710
|
(1)
|
1
|
|
887
|
3
|
2
|
|
357
|
(1)
|
1
|
|
466
|
(7)
|
(2)
|
|
Anoro Ellipta
|
127
|
7
|
9
|
|
47
|
7
|
5
|
|
56
|
8
|
12
|
|
24
|
4
|
13
|
|
Flixotide/Flovent
|
99
|
(29)
|
(27)
|
|
61
|
(36)
|
(37)
|
|
18
|
–
|
–
|
|
20
|
(23)
|
(12)
|
|
Relvar/Breo Ellipta
|
265
|
(2)
|
–
|
|
101
|
2
|
2
|
|
92
|
(6)
|
(4)
|
|
72
|
(1)
|
4
|
|
Seretide/Advair
|
216
|
(23)
|
(21)
|
|
56
|
(39)
|
(40)
|
|
50
|
(18)
|
(15)
|
|
110
|
(15)
|
(11)
|
|
Trelegy Ellipta
|
675
|
14
|
15
|
|
479
|
13
|
12
|
|
83
|
11
|
13
|
|
113
|
24
|
30
|
|
Ventolin
|
185
|
10
|
12
|
|
108
|
26
|
26
|
|
30
|
20
|
24
|
|
47
|
(18)
|
(14)
|
|
Other
Respiratory
|
143
|
(8)
|
(5)
|
|
35
|
59
|
59
|
|
28
|
(13)
|
(12)
|
|
80
|
(22)
|
(17)
|
|
Other
General Medicines
|
778
|
(7)
|
(3)
|
|
55
|
4
|
4
|
|
158
|
(12)
|
(9)
|
|
565
|
(7)
|
(2)
|
|
Augmentin
|
173
|
(7)
|
(2)
|
|
–
|
–
|
–
|
|
50
|
(7)
|
(6)
|
|
123
|
(7)
|
–
|
|
Lamictal
|
102
|
1
|
3
|
|
44
|
19
|
16
|
|
25
|
(11)
|
(7)
|
|
33
|
(8)
|
(3)
|
|
Other
General Medicines
|
503
|
(9)
|
(5)
|
|
11
|
(31)
|
(25)
|
|
83
|
(15)
|
(12)
|
|
409
|
(7)
|
(2)
|
|
General Medicines
|
2,488
|
(3)
|
–
|
|
942
|
3
|
2
|
|
515
|
(5)
|
(2)
|
|
1,031
|
(7)
|
(2)
|
Commercial Operations turnover
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
£m
|
AER%
|
CER%
|
|
Three months ended 31 March 2025
|
7,516
|
2
|
4
|
|
3,752
|
5
|
4
|
|
1,749
|
8
|
11
|
|
2,015
|
(6)
|
(2)
|
Segment information
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK reports results under two segments:
Commercial Operations and Total R&D. Members of the GLT are
responsible for each segment.
R&D
investment is essential for the sustainability of the business.
However, for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and is reported as a separate segment. The operating costs
of this segment includes R&D activities across Specialty
Medicines, including HIV and Vaccines. It includes R&D and some
SG&A costs relating to regulatory and other
functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
Adjusting
items reconciling segment profit and operating profit comprise
items not specifically allocated to segment profit. These include
impairment and amortisation of intangible assets, major
restructuring costs, which include impairments of tangible assets
and computer software, transaction-related adjustments related to
significant acquisitions, proceeds and costs of disposals of
associates, products and businesses, Significant legal charges and
expenses on the settlement of litigation and government
investigations, other operating income other than royalty income,
and other items including amounts reclassified from the foreign
currency translation reserve to the income statement upon the
liquidation of a subsidiary where the amount exceeds £25
million.
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|||||||
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
7,516
|
|
7,363
|
|
2
|
|
4
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,919
|
|
3,855
|
|
2
|
|
4
|
|
Research
and Development
|
(1,353)
|
|
(1,308)
|
|
3
|
|
4
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,566
|
|
2,547
|
|
1
|
|
4
|
|
Corporate
and other unallocated costs
|
(33)
|
|
(104)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
2,533
|
|
2,443
|
|
4
|
|
5
|
|
Adjusting
items
|
(317)
|
|
(953)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
2,216
|
|
1,490
|
|
49
|
|
50
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
54
|
|
32
|
|
|
|
|
|
Finance
costs
|
(162)
|
|
(166)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
–
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
2,108
|
|
1,355
|
|
56
|
|
57
|
Commercial
Operations Core operating profit of £3,919 million increased
in the quarter. Strong Specialty Medicines sales performance,
favourable product and regional mix, and higher royalty income were
partly offset by investment in new asset launches and growth
assets.
The
R&D segment operating expense of £1,353 million in the
quarter reflected continued spend across the portfolio, driven by
Oncology investment in ADCs with lower spend on Blenrep and Zejula as these studies progress to
completion. Investment in Specialty Medicines also increased
driven by camlipixant and the long acting TSLP asset.
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2024. At 31 March
2025, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 9) was
£1,351 million (31 December 2024: £1,446
million).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Annual Report
2024:
Product Liability
Zantac
As
previously disclosed, the vast majority of the remaining cases have
been resolved or dismissed such that less than 1% of the state
court cases remain. GSK is in negotiations with plaintiffs’
counsel on the remaining cases, including two cases in Nevada state
court with trials scheduled in 2026. The trial in the Mayor &
City of Baltimore action is scheduled to begin 28 September
2026.
The
appeal of the Delaware Superior Court’s decision allowing
plaintiffs to present expert evidence of general causation on all
ten cancer types to a jury remains pending. Oral argument was heard
before the Delaware Supreme Court on 16 April 2025. A
decision could be issued in Q2-Q3 2025.
As
previously disclosed, approximately 14,000 product liability cases
were dismissed following the grant of defendants’ Daubert
motions in December 2022 in the Federal MDL proceeding. These are
now on appeal by the plaintiffs to the United States Court of
Appeals for the Eleventh Circuit, along with appeals in the medical
monitoring and consumer class action cases. Oral argument is
tentatively scheduled for the week of 28 July 2025.
On 9
October 2024 GSK also reached an agreement to pay a total of $70
million to resolve the Zantac qui tam complaint previously filed by
Valisure. Both the Department of Justice and the participating
State Attorneys General approved the agreement which was signed on
3 April 2025. The qui tam
complaint will be dismissed.
Intellectual Property
mRNA
GSK
filed a patent infringement case against Pfizer/BioNTech in the
United States District Court for the District of Delaware alleging
infringement of 8 US GSK patents by the COVID-19 vaccine,
COMIRNATY®. Trial has been scheduled for 7 June
2027.
GSK
filed two separate patent infringement suits against Moderna, Inc.
in the United States District Court for the District of Delaware.
The first suit alleges infringement of 7 GSK patents by the
COVID-19 vaccine, SPIKEVAX®. Trial has been scheduled for 19
July 2027. The second suit alleges infringement of 6 GSK patents by
the RSV vaccine, mRESVIA®, and trial has been scheduled for 23
August 2027.
On 2
January 2025, Acuitas Therapeutics Inc. filed a declaratory
judgment complaint against GSK, seeking judgment that
COMIRNATY® does not infringe five GSK patents. Acuitas also
seeks a ruling that the patents are invalid. GSK has moved to
dismiss the complaint for lack of subject matter
jurisdiction.
RSV
On 1
April 2025, GSK and Pfizer Inc, reached a global settlement of all
litigation whereby Pfizer has been granted a worldwide license to
certain patents controlled by GSK relating to recombinant RSV
prefusion F protein and GSK will receive a royalty stream on sales
of Abrysvo®. The pending litigation in the United States
District Court for the District of Delaware was dismissed on 4
April 2025. Cases pending in other jurisdictions are also in the
process of being dismissed.
Returns to
shareholders
Quarterly dividends
The
Board has declared a first interim dividend for Q1 2025 of 16p per
share (Q1 2024: 15p per share).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 per cent pay-out ratio through the investment cycle. Consistent
with this, GSK has declared a dividend of 16p for Q1 2025. The
expected dividend for 2025 is 64p per share. In setting its
dividend policy, GSK considers the capital allocation priorities of
the Group and its investment strategy for growth alongside the
sustainability of the dividend.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 8 July 2025. An annual fee
of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the
Depositary. The ex-dividend and record dates will be 16 May 2025
with a payment date of 10 July 2025.
|
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2025
|
|
|
|
|
|
|
First
interim
|
10 July
2025
|
|
16
|
|
654
|
|
2024
|
|
|
|
|
|
|
First
interim
|
11 July
2024
|
|
15
|
|
612
|
|
Second
interim
|
10
October 2024
|
|
15
|
|
612
|
|
Third
interim
|
9
January 2025
|
|
15
|
|
612
|
|
Fourth
interim
|
10
April 2025
|
|
16
|
|
656
|
|
|
|
|
|
|
|
|
|
|
|
61
|
|
2,492
|
Share capital in issue
At 31
March 2025, 4,085 million shares (Q1 2024: 4,078 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). The company issued 0.9 million shares in the quarter (Q1
2024: 1.9 million) under employee share schemes for net proceeds of
£12 million (Q1 2024: £18 million).
On 5th
February 2025, GSK announced a £2 billion share buyback
programme to be completed over an 18 month period. As at 31 March
2025, 18 million shares were repurchased and are being held as
treasury shares, at a cost of £273 million, including
transaction costs of £1 million.
Treasury
shares for these purposes include shares purchased by GSK plc on 28
March 2025 and 31 March 2025. As announced via RNS, GSK purchased
834,200 ordinary shares on 28 March 2025 and 836,600 ordinary
shares on 31 March 2025, to be held as Treasury shares. Upon
settlement of the relevant trades, the shares purchased on those
dates are held as Treasury shares, and are therefore treated as
Treasury shares for the purposes of the Q1 2025 reporting period
and this results announcement. The settlement cost of these shares
was £25 million.
At 31
March 2025, the company held 187 million Treasury shares at a cost
of £3,230 million, of which 169 million shares of
£2,957 million were repurchased as part of previous share
buyback programmes, which has been deducted from retained
earnings.
At 31
March 2025, the ESOP Trusts held 43.6 million shares of GSK shares,
of which 43 million were held for the future exercise of share
options and share awards and 0.6 million were held for the
Executive Supplemental Savings plan. The carrying value of
£304 million has been deducted from other reserves.
The market value of these shares was £638
million.
Weighted average number of shares
The
numbers of shares used in calculating basic and diluted earnings
per share are reconciled below:
|
|
|
|
|
|
Weighted average number of shares
|
|||
|
|
Q1 2025
millions
|
|
Q1
2024
millions
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
4,088
|
|
4,069
|
|
Dilutive
effect of share options and share awards
|
49
|
|
44
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
4,137
|
|
4,113
|
Additional
information
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the three months ended 31 March 2025 and should be
read in conjunction with the Annual Report 2024, which was prepared
in accordance with UK- adopted international accounting standards
in conformity with the requirements of the Companies Act 2006 and
the International Financial Reporting Standards (IFRS) as issued by
the International Accounting Standards Boards (IASB). This Results
Announcement has been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report
2024.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2024.
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2024 were published
in the Annual Report 2024, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
Exchange rates
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2025
|
|
Q1
2024
|
|
2024
|
||
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
1.26
|
|
1.27
|
|
1.28
|
|
|
|
Euro/£
|
|
1.20
|
|
1.16
|
|
1.18
|
|
|
|
Yen/£
|
|
193
|
|
187
|
|
193
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
1.29
|
|
1.26
|
|
1.25
|
|
|
|
Euro/£
|
|
1.20
|
|
1.17
|
|
1.20
|
|
|
|
Yen/£
|
|
193
|
|
191
|
|
197
|
Contingent liabilities
There
were contingent liabilities at 31 March 2025 in respect of
arrangements entered into as part of the ordinary course of the
Group’s business. No material losses are expected to arise
from such contingent liabilities. Provision is made for the outcome
of legal and tax disputes where it is both probable that the Group
will suffer an outflow of funds and it is possible to make a
reliable estimate of that outflow. Descriptions of the Significant
legal disputes to which the Group is a party are set out on page
30, and pages 287 to 290 of the 2024 Annual Report.
Net assets
The
book value of net assets increased by £568 million from
£13,086 million at 31 December 2024 to £13,654 million at
31 March 2025. This primarily reflected contribution from Total
comprehensive income for the period partly offset by dividends paid
to shareholders and shares committed to be repurchased under the
first tranche of the 2025 share buyback programme and associated
transaction costs.
At 31
March 2025, the net deficit on the Group’s pension plans
decreased to £18 million compared with £103 million at 31
December 2024. This decrease is primarily due to an increase in the
UK discount rate and a decrease in the UK inflation rate, partly
offset by a decrease in the US discount rate, and lower UK and US
asset values.
Other
payables includes £428 million related to shares still to be
purchased as part of the first tranche of the 2025 share buyback
programme, £25 million for shares purchased but not settled at
31 March 2025, and £1 million of transaction
costs.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £855 million (31
December 2024: £915 million).
Contingent
consideration amounted to £7,029 million at 31 March 2025 (31
December 2024: £7,280 million) as follows:
|
|
|
|
|
|
|
Group
31 March
2025
£m
|
|
Group
31
December 2024
£m
|
|
|
|
|
|
|
Contingent
consideration estimated present value of amounts payable relating
to:
|
|
|
|
|
Former
Shionogi-ViiV Healthcare joint venture
|
5,769
|
|
6,061
|
|
Former
Novartis Vaccines business acquisition
|
605
|
|
575
|
|
Affinivax
acquisition
|
454
|
|
502
|
|
Aiolos
acquisition
|
129
|
|
130
|
|
Others
|
72
|
|
12
|
|
|
|
|
|
|
Contingent
consideration liability at end of the period
|
7,029
|
|
7,280
|
Of the
contingent consideration payable to Shionogi at 31 March 2025,
£1,120 million (31 December 2024: £1,127 million) is
expected to be paid within one year.
Movements
in contingent consideration are as follows:
|
|
|
|
|
|
Q1 2025
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
6,061
|
|
7,280
|
|
Additions
|
–
|
|
61
|
|
Remeasurement
through income statement and other movements
|
39
|
|
29
|
|
Cash
payments: operating cash flows
|
(331)
|
|
(338)
|
|
Cash
payments: investing activities
|
–
|
|
(3)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,769
|
|
7,029
|
|
|
|
|
|
|
Q1
2024
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,718
|
|
6,662
|
|
Remeasurement
through income statement and other movements
|
586
|
|
722
|
|
Cash
payments: operating cash flows
|
(300)
|
|
(306)
|
|
Cash
payments: investing activities
|
–
|
|
(3)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
6,004
|
|
7,075
|
Business acquisitions
On 13
January 2025, GSK announced it had entered into an agreement to
acquire 100% of IDRx, Inc, a Boston based, clinical stage
biopharmaceutical company dedicated to developing precision
therapies for the treatment of gastrointestinal stromal tumours
(GIST). The acquisition includes lead molecule, IDRX-42, a highly
selective investigational tyrosine kinase inhibitor (TKI) that is
designed to improve the outcomes for patients with GIST. GSK
acquired all of the outstanding equity interests in IDRx for a
total consideration of US$1.1 billion (£840 million) as
adjusted for working capital acquired paid upon closing and up to
US$150 million (£119 million) as an additional
success-based regulatory milestone payment. The estimated fair
value of the contingent consideration payable was US$60 million
(£48 million). In addition, GSK will also be responsible for
success-based milestone payments as well as tiered royalties for
IDRX-42 owed to Merck KGaA, Darmstadt, Germany. The transaction was
subject to customary conditions, including applicable regulatory
agency clearances under the Hart Scott-Rodino Act in the US, and
subsequently closed on 21 February 2025.
The
initial acquisition accounting was reflected in the first quarter
of 2025 on a preliminary basis, the values below are provisional
and subject to change. The purchase price allocation is expected to
be completed by the end of Q4 2025.
Goodwill
of £88 million has been recognised. The goodwill represents
specific synergies available to GSK from the business combination.
The goodwill has been allocated to the Group’s R&D
segment.
The
provisional fair values of the net assets acquired, including
goodwill, are as follows:
|
|
|
|
|
|
|
|
|
£m
|
|
Net
assets acquired:
|
|
|
|
|
Intangible
assets
|
|
|
1,007
|
|
Cash
and cash equivalents
|
|
|
48
|
|
Other
net liabilities
|
|
|
(52)
|
|
Deferred
tax liabilities
|
|
|
(203)
|
|
|
|
|
800
|
|
Goodwill
|
|
|
88
|
|
Total
consideration
|
|
|
888
|
Of the
£888 million consideration, £63 million was unpaid as at
31 March 2025.
On 15
January 2025, GSK acquired a Berlin based private company,
Cellphenomics GmbH, which has developed proprietary capabilities in
developing durable organoid models, for a total cash consideration
of up to €44 million (approximately £37 million) of
which €15 million (£13 million) was unpaid as at 31
March 2025. The acquisition is accounted for as a business
combination but is not considered a significant acquisition for the
Group. This agreement was not subject to closing conditions and the
acquisition has been completed.
|
|
|
Net debt
information
|
|
|
|
Reconciliation of cash flow to movements in net debt
|
|
|
|
|
|
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
Total
Net debt at beginning of the period
|
(13,095)
|
|
(15,040)
|
|
Increase/(decrease)
in cash and bank overdrafts
|
859
|
|
(251)
|
|
Increase/(decrease)
in liquid investments
|
–
|
|
(22)
|
|
Issue
of long-term notes
|
(2,018)
|
|
–
|
|
Net
decrease/(increase) in short-term loans
|
–
|
|
323
|
|
Increase
in other short-term loans(1)
|
(59)
|
|
–
|
|
Repayment
of other short-term loans(1)
|
159
|
|
–
|
|
Repayment
of lease liabilities
|
57
|
|
57
|
|
Net
debt of subsidiary undertakings acquired
|
(1)
|
|
–
|
|
Exchange
adjustments
|
187
|
|
1
|
|
Other
non-cash movements
|
(36)
|
|
(29)
|
|
Decrease/(increase)
in net debt
|
(852)
|
|
79
|
|
Total
Net debt at end of the period
|
(13,947)
|
|
(14,961)
|
|
|
|
|
(1)
|
Other short-term loans include bank
loans presented within short-term borrowings on the balance sheet,
with an initial maturity of greater than three months but less than
twelve months.
|
|
|
|
Net debt analysis
|
|
|
|
|
|
|
|
31 March 2025
£m
|
|
31
December 2024
£m
|
|
Liquid
investments
|
21
|
|
21
|
|
Cash
and cash equivalents
|
4,464
|
|
3,870
|
|
Short-term
borrowings
|
(1,958)
|
|
(2,349)
|
|
Long-term
borrowings
|
(16,474)
|
|
(14,637)
|
|
Total
Net debt at the end of the period
|
(13,947)
|
|
(13,095)
|
|
|
|
Free cash flow reconciliation
|
|
|
|
|
|
|
|
Q1 2025
£m
|
|
Q1
2024
£m
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
1,145
|
|
958
|
|
Purchase
of property, plant and equipment
|
(208)
|
|
(248)
|
|
Proceeds
from sale of property, plant and equipment
|
1
|
|
1
|
|
Purchase
of intangible assets
|
(240)
|
|
(315)
|
|
Proceeds
from disposals of intangible assets
|
76
|
|
27
|
|
Net
finance costs
|
(16)
|
|
(34)
|
|
Contingent
consideration paid (reported in investing activities)
|
(3)
|
|
(3)
|
|
Distributions
to non-controlling interests
|
(58)
|
|
(97)
|
|
|
|
|
|
|
Free
cash inflow/(outflow)
|
697
|
|
289
|
Related party transactions
Details
of GSK’s related party transactions are disclosed on page 258
of the 2024 Annual Report.
|
|
|
R&D
commentary
|
|
|
|
Pipeline overview
|
|
|
|
|
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
18
|
Respiratory, Immunology and Inflammation (6)
|
|
|
●
|
Nucala (anti-IL5 biologic) chronic obstructive pulmonary
disease
|
||
|
●
|
depemokimab
(ultra long-acting anti-IL5 biologic) severe eosinophilic asthma,
eosinophilic granulomatosis with polyangiitis (EGPA), chronic
rhinosinusitis with nasal polyps (CRSwNP), hyper-eosinophilic
syndrome (HES)
|
||
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
||
|
●
|
camlipixant
(P2X3 receptor antagonist) refractory chronic cough
|
||
|
●
|
Ventolin (salbutamol, Beta 2 adrenergic receptor agonist)
asthma
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Oncology (5)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer, colon cancer,
rectal cancer, head and neck cancer
|
||
|
●
|
Zejula (PARP inhibitor) 1L ovarian and non-small cell lung
cancer, glioblastoma
|
||
|
●
|
belrestotug
(anti-TIGIT) 1L non-small cell lung cancer
|
||
|
●
|
cobolimab
(anti-TIM-3) 2L non-small cell lung cancer
|
||
|
Infectious Diseases (7)
|
|||
|
●
|
Arexvy (RSV vaccine) RSV adults (18-49 years of age at
increased risk (AIR) and 18+ immunocompromised)
|
||
|
●
|
Blujepa (gepotidacin; bacterial topoisomerase inhibitor)
uncomplicated urinary tract infection and urogenital
gonorrhoea
|
||
|
●
|
bepirovirsen
(HBV ASO) hepatitis B virus
|
||
|
●
|
Bexsero (meningococcal B vaccine) infants (US)
|
||
|
●
|
tebipenem
pivoxil (antibacterial carbapenem) complicated urinary tract
infection
|
||
|
●
|
ibrexafungerp
(antifungal glucan synthase inhibitor) invasive
candidiasis
|
||
|
●
|
GSK4178116
(varicella vaccine) varicella new strain individuals 12 months of
age and older
|
||
|
Total
medicines and vaccines in all phases of clinical
development
|
70
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
91
|
|
|
Therapy area updates
The
following provides updates on key medicines and vaccines by therapy
area that will help drive growth for GSK to meet its future
outlooks.
Respiratory, Immunology and Inflammation
camlipixant (P2X3 receptor antagonist)
Camlipixant
(BLU-5937) is an investigational, highly selective oral P2X3
antagonist currently in development for first-line treatment of
adult patients suffering from refractory chronic cough (RCC). The
CALM phase III development programme to evaluate the efficacy and
safety of camlipixant for use in adults with RCC is
ongoing.
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
CALM-1
(refractory chronic cough)
NCT05599191
|
III
|
A
52-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q4
2022
|
Recruiting
|
|
CALM-2
(refractory chronic cough)
NCT05600777
|
III
|
A
24-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q1
2023
|
Recruiting
|
depemokimab (long acting anti-IL5)
Depemokimab
is in late-stage development in a range of IL-5 mediated conditions
including asthma with type 2 inflammation, chronic rhinosinusitis
with nasal polyps (CRSwNP), hypereosinophilic syndrome (HES) and
eosinophilic granulomatosis with polyangiitis (EGPA). It is the
first ultra-long-acting biologic engineered to have an extended
half-life and high binding affinity and potency for IL-5, enabling
six-month dosing intervals in phase III clinical
trials.
Positive
phase III data from the pivotal SWIFT-1 and SWIFT-2 trials in
asthma with type 2 inflammation and the ANCHOR-1 and ANCHOR-2
trials in patients with CRSwNP have been published in The New England
Journal of Medicine and The Lancet
respectively and are being used to support regulatory filings in
major markets.
Regulatory
submissions seeking approval for the use of depemokimab in patients
with asthma with type 2 inflammation and in patients with CRSwNP,
have been accepted by the health authorities in four major markets;
EU, China, Japan and the US. Submissions in other markets are
expected to progress through the year.
Key
phase III trials for depemokimab:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1
(severe asthma)
NCT04719832
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
|
SWIFT-2
(severe asthma)
NCT04718103
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
|
AGILE
(severe asthma)
NCT05243680
|
III
(exten
sion)
|
A
52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial
start:
Q1
2022
|
Active,
not recruiting
|
|
NIMBLE
(severe asthma)
NCT04718389
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial
start:
Q1
2021
|
Active,
not recruiting
|
|
ANCHOR-1
(chronic rhinosinusitis with nasal polyps; CRSwNP)
NCT05274750
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported: Q3 2024
|
Complete;
primary endpoint met
|
|
ANCHOR-2
(CRSwNP)
NCT05281523
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
OCEAN
(eosinophilic granulomatosis with polyangiitis; EGPA)
NCT05263934
|
III
|
Efficacy
and safety of depemokimab compared with mepolizumab in adults with
relapsing or refractory EGPA
|
Trial
start:
Q3
2022
|
Recruiting
|
|
DESTINY
(hyper-eosinophilic syndrome; HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial
start:
Q3
2022
|
Recruiting
|
Nucala (mepolizumab)
Nucala is a first in class anti-IL-5 biologic and the only
treatment approved for use in the US and Europe across four IL-5
medicated conditions: severe asthma with an eosinophilic phenotype,
EGPA, HES and CRSwNP.
In
September 2024, positive results from MATINEE, a phase III trial
investigating mepolizumab in patients with chronic obstructive
pulmonary disease (COPD) were announced. MATINEE met its primary
endpoint with the addition of mepolizumab to inhaled maintenance
therapy showing a statistically significant and clinically
meaningful reduction in the annualised rate of moderate/severe
exacerbations versus placebo, with patients treated for up to 104
weeks. Publication of the full results of MATINEE is expected in Q2
2025.
In Q1
2025, regulators in the EU and China accepted the MATINEE data for
review as part of the regulatory process to seek an indication for
the use of mepolizumab in patients with COPD. Regulatory review in
the US is ongoing with a decision expected in May
2025.
Key
trials for Nucala:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MATINEE
(chronic obstructive pulmonary disease; COPD)
NCT04133909
|
III
|
A
multicentre randomised, double-blind, parallel-group,
placebo-controlled trial of mepolizumab 100 mg subcutaneously as
add-on treatment in participants with COPD experiencing frequent
exacerbations and characterised by eosinophil levels
|
Trial
start:
Q4
2019
Data
reported:
Q3
2024
|
Complete;
primary endpoint met
|
Oncology
Blenrep (belantamab
mafodotin)
Based
on positive results from the phase III head-to-head DREAMM-7 and
DREAMM-8 trials, GSK is pursuing regulatory approvals worldwide for
Blenrep combinations for
the treatment of relapsed or refractory multiple myeloma. In April
2025, the UK’s Medicines and Healthcare products Regulatory
Agency (MHRA) approved Blenrep in second line and later
multiple myeloma, its first regulatory approval in this treatment
setting anywhere in the world. Additional submissions are under
review in 14 markets, with key approvals expected in major markets
in 2025, including the US with a Prescription Drug User Fee Act
(PDUFA) date of 23 July.
GSK
continues to explore the potential for belantamab mafodotin to help
address unmet need for patients with multiple myeloma, in early
treatment lines and in combination with novel therapies and
standard of care treatments through the DREAMM clinical trial
programme. The programme includes DREAMM-10, a phase III trial
evaluating belantamab mafodotin plus lenalidomide and dexamethasone
(BRd) versus daratumumab plus lenalidomide and dexamethasone (DRd)
in patients with newly diagnosed transplant ineligible multiple
myeloma.
Key
phase III trials for Blenrep:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7
(2L+ multiple myeloma; MM)
NCT04246047
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4 2023
|
Active,
not recruiting; primary endpoint met
|
|
DREAMM-8
(2L+ MM)
NCT04484623
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Active,
not recruiting, primary endpoint met
|
|
DREAMM-10
(1L MM)
NCT06679101
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin, lenalidomide and dexamethasone
(B-Rd) versus daratumumab, lenalidomide, and dexamethasone (D-Rd)
in participants with newly diagnosed multiple myeloma who are
ineligible for autologous stem cell transplantation
|
Trial
start:
Q4
2024
|
Recruiting
|
Jemperli (dostarlimab)
Jemperli (dostarlimab) is the foundation of GSK’s
immuno-oncology-based research and development programme. It is the
only approved immuno-oncology-based treatment regimen to
demonstrate a statistically significant and clinically meaningful
overall survival benefit for the first-line treatment of adult
patients with primary advanced or recurrent endometrial cancer
irrespective of biomarker status. The ongoing development
programme includes our AZUR trials in dMMR/MSI-H locally advanced
rectal cancer and resectable dMMR/MSI-H colon cancer; our JADE
phase III trial in locally advanced unresected head and neck
cancer; our COSTAR Lung phase III trial in combination with
anti-TIM-3 compound cobolimab and chemotherapy in second-line
non-small cell lung cancer (NSCLC); and the GALAXIES-Lung-301 phase
III trial in combination with anti-TIGIT compound belrestotug in
firstline locally advanced or metastatic PD-1-selected
NSCLC.
Key
trials for Jemperli:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
|
PERLA
(1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A
randomised, double-blind trial to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial
start:
Q4
2020
Primary
data reported:
Q4
2022
|
Complete;
primary endpoint met
|
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multi-centre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Recruiting
|
|
AZUR-1
(locally advanced rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
|
Active,
not recruiting
|
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III dMMR/MSI-H resectable colon cancer
|
Trial
start:
Q3
2023
|
Recruiting
|
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
|
Recruiting
|
|
COSTAR
Lung (advanced non-small cell lung cancer that has progressed on
prior PD-(L)1 therapy and chemotherapy)
NCT04655976
|
II/III
|
A
multi-centre, randomised, parallel group treatment, open label
trial comparing cobolimab + dostarlimab + docetaxel to dostarlimab
+ docetaxel to docetaxel alone in participants with advanced
non-small cell lung cancer who have progressed on prior
anti-PD-(L)1 therapy and chemotherapy
|
Trial
start:
Q4
2020
|
Active,
not recruiting
|
|
GALAXIES-Lung
301 (untreated, unresectable, locally advanced or metastatic PD-L1
high non-small cell lung cancer)
NCT06472076
|
III
|
A
randomized, multicenter, double-blind, trial investigating
belrestotug in combination with dostarlimab compared with placebo
in combination with pembrolizumab in participants with previously
untreated, unresectable, locally advanced or metastatic PD-L1
selected non-small cell lung cancer
|
Trial
start:
Q2
2024
|
Recruiting
|
Zejula (niraparib)
GSK
continues to assess the potential of niraparib monotherapy and in
combination with other agents across multiple tumour types.
Niraparib monotherapy is being evaluated in patients with newly
diagnosed, MGMT unmethylated glioblastoma in the phase III
GLIOFOCUS trial (NCT06388733) sponsored by the Ivy Brain Tumor
Center and supported by GSK. In addition, the ongoing development
programme includes several phase III combination studies including
the RUBY Part 2 trial of niraparib and dostarlimab in recurrent or
primary advanced endometrial cancer; the FIRST trial of niraparib
and dostarlimab in stage III or IV nonmucinous epithelial ovarian
cancer; and the ZEAL-1L trial of niraparib plus pembrolizumab in
advanced/metastatic non-small cell lung cancer.
In
April 2025, results showed that the phase III ZEAL-1L trial did not
meet its primary endpoint of progression-free survival. There were
no new safety findings; safety results were generally consistent
with the known safety profile of each individual agent. GSK is
planning to present the results at an upcoming scientific meeting.
Results will be shared with global health authorities as
appropriate.
Key
ongoing phase III trials for Zejula (see also RUBY Part 2 in
Jemperli
section):
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L
(1L advanced non-small cell lung cancer maintenance)
NCT04475939
|
III
|
A
randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial
start:
Q4
2020
Data
reported: Q1 2025
|
Active
not recruiting, has results
|
|
FIRST
(1L ovarian cancer maintenance)
NCT03602859
|
III
|
A
randomised, double-blind, comparison of platinum-based therapy with
dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial
start:
Q4
2018
Data
reported:
Q4
2024
|
Complete:
primary endpoint met
|
HIV
As
pioneers in long-acting injectables, GSK is focused on the
next-generation of HIV innovation with integrase inhibitors
(INSTIs) – the gold standard for HIV treatment and prevention
– at the core. We remain confident that our pipeline -
including three new INSTIs in development and five planned
launches, will continue to drive performance over the coming
decade.
In
March 2025, ViiV Healthcare, majority owned by GSK, shared 81
abstracts at CROI (Conference on Retroviruses and Opportunistic
Infections), the premier scientific HIV conference. Data spanned
our innovative HIV treatment and prevention portfolio, and
pipeline, reinforcing our position as leaders in HIV innovation
with a focus on long-acting injectables.
Key
data included real-world and implementation data highlighting the
effectiveness Cabenuva
(cabotegravir + rilpivirine LA) and Apretude (cabotegravir LA (CAB LA) for
PrEP) - the only approved long-acting injectable therapies for HIV
treatment and prevention dosed every two-months - among a broad
range of populations. These data reinforce confidence in the
competitive profile, efficacy, safety and tolerability of our
long-acting medicines delivering on the needs of patients
today.
Data
were also shared highlighting the progress of three high potential
assets in our treatment pipeline:
●VH184 (third generation INSTI):
phase IIa results demonstrated rapid and high potency, positive
safety results and no drug resistance mutations. These promising
early data support further development of VH184 as the backbone of
the next generation of HIV treatment regimens.
●N6LS (bNAb): phase IIb data showed
high efficacy and tolerability. These results combined with
pharmacokinetic (PK) data support progressing this asset to explore
six-monthly dosing.
●VH499 (investigational capsid
inhibitor): phase IIa data showed potent antiviral activity and
favourable safety, supporting further development of this
asset.
The
assets that will deliver six-monthly dosing for treatment are
expected to be confirmed in 2026, with a Q6M registrational study
start planned in 2027. We expect our Q6M regimen to contain a
combination of one of three long-acting INSTIs (CAB ULA, VH184 or
VH310) with either our bNAB N6LS or VH499, our capsid
inhibitor.
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EXTEND
4M (HIV)
NCT06741397
|
II
|
Phase
IIb open label, single arm, repeat dose study to investigate the
safety, tolerability and pharmacokinetics (PK) of CAB ULA
administered intramuscularly every four months in participants at
risk of acquiring HIV-1.
|
Trial
start:
Q4
2024
|
Active,
not recruiting
|
|
EMBRACE
(HIV)
NCT05996471
|
IIb
|
The
study aims at evaluating the efficacy of VH3810109, dosed in
accordance with the dosing schedule as either intravenous (IV)
infusion or subcutaneous (SC) infusion with recombinant
hyaluronidase (rHuPH20), in combination with cabotegravir (CAB)
intramuscular (IM) dosed in accordance with the dosing schedule in
virologically suppressed, Antiretroviral therapy (ART)-experienced
adult participants living with HIV.
|
Q3
2023
|
Active,
not recruiting
|
Infectious Diseases
Arexvy (respiratory
syncytial virus vaccine, adjuvanted)
GSK
continues to generate data strengthening the body of evidence
supporting the robust profile of its RSV vaccine for adults,
Arexvy. In March 2025, 17
abstracts were presented at the International RSV Symposium in
Brazil to further evaluate the unmet medical need associated with
RSV and disclose new data on the immunogenicity and safety of
Arexvy. Positive data on
the co-administration of Arexvy with the standard of care for
adult pneumococcal vaccination (PCV20) were disclosed at the
congress of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) in April.
In
April 2025, the Advisory Committee on Immunization Practices (ACIP)
voted in favour of recommending the use of RSV vaccines including
Arexvy in adults aged 50-59
who are at increased risk for severe RSV disease. This represents
over 13 million people, including those with conditions like COPD,
asthma, diabetes, heart disease and those in residential care. This
expands on ACIP’s previous vote in June 2024 to recommend RSV
vaccines for adults aged 60-74 who are at increased risk and all
adults aged 75 and older. The vaccine has now been approved for use
in 66 markets worldwide.
Key
phase III trials for Arexvy:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-004
(Adults
≥ 60 years old)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-006
(ARESVI-006;
Adults ≥ 60 years old)
NCT04886596
|
III
|
A
randomised, placebo-controlled, observer-blind, multi-country trial
to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial
start:
Q2
2021
Primary
data reported:
Q2
2022;
two
season data reported:
Q2
2023;
three
season data reported: Q3 2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-012
(Adults
aged 60 years and above)
NCT06534892
|
IIIb
|
An
Extension and Crossover Vaccination Study on the Immune Response
and Safety of a Vaccine Against Respiratory Syncytial Virus Given
to Adults 60 Years of Age and Above Who Participated in RSV
OA=ADJ-006 Study
|
Trial
start:
Q3
2024
|
Recruiting
|
|
RSV
OA=ADJ-007
(Adults
≥ 60 years old)
NCT04841577
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with FLU-QIV vaccine
in adults aged 60 years and above
|
Trial
start:
Q2
2021
Primary
data reported:
Q4
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-008
(Adults
≥ 65 years old)
NCT05559476
|
III
|
A phase
III, open-label, randomised, controlled, multi country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU HD vaccine
in adults aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-009
(Adults
≥ 60 years old)
NCT05059301
|
III
|
A
randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial
start:
Q4
2021
Trial
end:
Q2
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-017
(Adults
≥ 65 years old)
NCT05568797
|
III
|
A phase
III, open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of an
RSVPreF3 OA investigational vaccine when co-administered with FLU
aQIV (inactivated influenza vaccine – adjuvanted) in adults
aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete;
data analysis ongoing
|
|
RSV
OA=ADJ-018
(Adults
50-59 years)
NCT05590403
|
III
|
A phase
III, observer-blind, randomised, placebo-controlled trial to
evaluate the non-inferiority of the immune response and safety of
the RSVPreF3 OA investigational vaccine in adults 50-59 years of
age, including adults at increased risk of respiratory syncytial
virus lower respiratory tract disease, compared to older adults
≥60 years of age
|
Trial
start:
Q4
2022
Primary
data reported:
Q4
2023
|
Complete;
primary endpoint met
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key
phase III trials for Arexvy
(continued):
|
|
|
||
|
RSV
OA=ADJ-019
(Adults
≥ 60 years old)
NCT05879107
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with PCV20 in adults
aged 60 years and older
|
Trial
start:
Q2
2023
Primary
data reported: Q1 2025
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-023
(Immunocompromised
Adults 50-59 years)
NCT05921903
|
IIb
|
A
randomised, controlled, open-label trial to evaluate the immune
response and safety of the RSVPreF3 OA investigational vaccine in
adults (≥50 years of age) when administered to lung and renal
transplant recipients comparing one versus two doses and compared
to healthy controls (≥50 years of age) receiving one
dose
|
Trial
start:
Q3
2023
Primary
data reported:
Q4
2024
|
Active,
not recruiting; primary endpoint met
|
|
RSV-OA=ADJ-020
(Adults
aged >=50 years of age)
NCT05966090
|
III
|
A study
on the safety and immune response of investigational RSV OA vaccine
in combination with herpes zoster vaccine in healthy
adults
|
Trial
start:
Q3
2023
Primary
data reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
RSV-OA=ADJ-013
(Adults
aged 50 years and above)
NCT06374394
|
III
|
An
open-label, randomized, controlled study to evaluate the immune
response, safety and reactogenicity of RSVPreF3 OA investigational
vaccine when co-administered with a COVID-19 mRNA
vaccine
|
Trial
start:
Q2
2024
|
Active,
not recruiting
|
|
RSV
OA=ADJ-025
(Adults,
18-49 years of age, at increased risk for RSV disease and older
adult participants, >=60 YOA)
NCT06389487
|
IIIb
|
An
open-label study to evaluate the non-inferiority of the immune
response and to evaluate the safety of the RSVPreF3 OA
investigational vaccine in adults 18-49 years of age at increased
risk for Respiratory Syncytial Virus disease, compared to older
adults >=60 years of age
|
Trial
start:
Q2
2024
Primary
data reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-021
(Adults
aged 60 years and above)
NCT06551181
|
III
|
A study
on the immune response, safety and the occurrence of Respiratory
Syncytial Virus (RSV)-associated respiratory tract illness after
administration of RSV OA vaccine in adults 60 years and older in
China and other countries
|
Trial
start:
Q3
2024
|
Recruiting
|
bepirovirsen (HBV ASO)
Bepirovirsen,
a triple-action antisense oligonucleotide, is a potential new
treatment option for people with chronic hepatitis B (CHB) that has
been granted Fast Track designation by the US FDA and SENKU
designation by the Japanese Ministry of Health, Labour and Welfare
in Japan for the treatment of CHB. To further expand development in
novel sequential regimens, GSK has entered an agreement for an
exclusive worldwide license to develop and commercialise
daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), an
investigational hepatitis B virus-targeted small interfering
ribonucleic acid (siRNA) therapeutic. This agreement provides an
opportunity to investigate a novel sequential regimen to pursue
functional cure in an even broader patient population with
bepirovirsen. Phase IIb trials started in Q4 2024.
Key
trials for bepirovirsen:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Active,
not recruiting
|
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Active,
not recruiting
|
|
B-United
bepirovirsen sequential therapy with daplusiran/tomligisiran in
nucleos(t)ide treated patients (chronic hepatitis B)
NCT06537414
|
IIb
|
A
multi-centre, randomized, partially placebo-controlled,
double-blind study to investigate the safety and efficacy of
sequential therapy with daplusiran/tomligisiran followed by
bepirovirsen in participants with chronic hepatitis B virus on
background nucleos(t)ide analogue therapy
|
Trial
start:
Q4
2024
|
Recruiting
|
Blujepa (gepotidacin; bacterial topoisomerase
inhibitor)
In
March 2025, the US FDA approved Blujepa (gepotidacin) for the treatment
of female adults (≥40 kg) and paediatric patients (≥12
years, ≥40 kg) with uncomplicated urinary tract infections
(uUTIs) caused by the following susceptible microorganisms:
Escherichia coli, Klebsiella
pneumoniae, Citrobacter freundii complex, Staphylococcus
saprophyticus and Enterococcus faecalis. This is the
first in a new class of oral antibiotics for uUTIs in nearly 30
years.
Blujepa is a first-in-class oral antibiotic with a novel
mechanism of action that is part of GSK’s infectious diseases
portfolio. It is also being investigated for the treatment of
urogenital gonorrhoea. Positive data from three pivotal trials
demonstrate its potential to provide a new oral treatment option
for patients, including those with drug resistant infections.
Filings for gonorrhoea are expected to follow later in
2025.
Key
phase III trials for gepotidacin:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1
(uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A
randomised, multi-centre, open-label trial in adolescent and adult
participants comparing the efficacy and safety of gepotidacin to
ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial
start:
Q4
2019
Data
reported:
Q1
2024
|
Complete;
primary
endpoint met
|
|
EAGLE-2
(females with uUTI / acute cystitis)
NCT04020341
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q4
2019
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
EAGLE-3
(females with uUTI / acute cystitis)
NCT04187144
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q2
2020
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
Penmenvy
(MenABCWY
vaccine)
In
February 2025, the US FDA approved Penmenvy (Meningococcal Groups A, B, C,
W, and Y Vaccine) for use in individuals aged 10 through 25 years.
The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and
Y) which commonly cause invasive meningococcal disease
(IMD).
In
April 2025, the ACIP voted to recommend its use as part of the US
adolescent meningococcal vaccination schedule. GSK is working to
fulfil all post-marketing requirements.
GSK’s
5-in-1 meningococcal groups A, B, C, W, and Y (MenABCWY) vaccine
combines the antigenic components of its two well-established
licensed meningococcal vaccines – Bexsero (Meningococcal Group B Vaccine)
and Menveo (Meningococcal
Groups A, C, Y, and W-135 Vaccine). Its safety data demonstrates a
safety profile consistent with these two vaccines. The protection
offered by Penmenvy aims to
reduce the number of injections, simplifying immunisation and
potentially increasing series completion and vaccination coverage
of adolescents and young adults in the United States.
Key
trials for Penmenvy:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY
– 019
NCT04707391
|
IIIb
|
A
randomised, controlled, observer-blind trial to evaluate safety and
immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial
start:
Q1
2021
Data
reported:
Q1
2024
|
Complete;
primary endpoints met
|
|
MenABCWY
– V72 72
NCT04502693
|
III
|
A
randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
Data
reported:
Q1
2023
|
Complete;
primary endpoints met
|
Reporting
definitions
CAGR (Compound annual growth rate)
CAGR is
defined as the compound annual growth rate and shows the annualised
average rate for growth in sales and core operating profit between
2021 to 2026, assuming growth takes place at an exponentially
compounded rate during those years.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. For
those countries which qualify as hyperinflationary as defined by
the criteria set out in IAS 29 ‘Financial Reporting in
Hyperinflationary Economies’ (Argentina and Turkey) CER
growth is adjusted using a more appropriate exchange rate where the
impact is significant, reflecting depreciation of their respective
currencies in order to provide comparability and not to distort CER
growth rates.
AER%
represents growth at actual exchange rates.
Core Earnings per
share
Unless
otherwise stated, Core earnings per share refers to Core basic
earnings per share.
Core Operating Margin
Core
Operating margin is Core operating profit divided by
turnover.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests,
contributions from non-controlling interests plus proceeds from the
sale of property, plant and equipment and intangible assets, and
dividends received from joint ventures and associates. The measure
is used by management as it is considered a good indicator of net
cash generated from business activities (excluding any cash flows
arising from equity investments, business acquisitions or disposals
and changes in the level of borrowing) available to pay
shareholders dividends and to fund strategic plans. Free cash flow
growth is calculated on a reported basis. A reconciliation of net
cash inflow from operations to free cash flow from operations is
set out on page 35.
Free cash flow conversion
Free
cash flow conversion is free cash flow from operations as a
percentage of profit attributable to shareholders.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines for inhaled respiratory, dermatology,
antibiotics and other diseases.
Non-controlling interest
Non-controlling
interest is the equity in a subsidiary not attributable, directly
or indirectly, to a parent.
Percentage points
Percentage
points of growth which is abbreviated to ppts.
RAR (Returns and Rebates)
GSK
sells to customers both commercial and government mandated
contracts with reimbursement arrangements that include rebates,
chargebacks and a right of return for certain pharmaceutical
products principally in the US. Revenue recognition reflects
gross-to-net sales adjustments as a result. These adjustments are
known as the RAR accruals and are a source of significant
estimation uncertainty and fluctuation which can have a material
impact on reported revenue from one accounting period to the
next.
Risk adjusted sales
Pipeline
risk-adjusted sales are based on the latest internal estimate of
the probability of technical and regulatory success for each asset
in development.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines for infectious diseases, HIV, Respiratory, Immunology and
Inflammation, and Oncology.
Total Net debt
Net
debt is defined as total borrowings less cash, cash equivalents,
liquid investments, and short-term loans to third parties that are
subject to an insignificant risk of change in value. The measure is
used by management as it is considered a good indicator of GSK's
ability to meet its financial commitments and the strength of its
balance sheet.
Total and Core results
Total
reported results represent the Group’s overall performance.
GSK uses a number of non-IFRS measures to report the performance of
its business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior
to, information presented in accordance with IFRS. Core results are
defined on page 17 and other non-IFRS measures are defined in pages
44 and 45.
Total Operating Margin
Total
Operating margin is Total operating profit divided by
turnover.
Total Earnings per
share
Unless
otherwise stated, Total earnings per share refers to Total basic
earnings per share.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
Brand names and
partner acknowledgements: brand names appearing in italics
throughout this document are trademarks of GSK or associated
companies or used under licence by the Group.
Guidance and Outlooks, assumptions and cautionary
statements
2025 Guidance
GSK
affirms its full-year 2025 guidance at constant exchange rates
(CER).
GSK
expects its turnover to increase between 3 to 5 per cent and Core
operating profit to increase between 6 to 8 per cent. Core earnings
per share is expected to increase between 6 to 8 per
cent.
The
Core earnings per share guidance includes the implementation of the
£2 billion share buyback programme to the end of Q2
2026.
The
Group has made planning assumptions that we expect turnover for
Specialty Medicines to increase by a low double-digit per cent,
Vaccines to decrease by a low-single digit per cent, and General
Medicines to be broadly stable.
Tariffs
GSK
notes that the US Administration has initiated an investigation
under Section 232 of the Trade Expansion Act to determine the
effects on national security of imports of pharmaceutical products.
The company is well positioned to respond to the potential
financial impact of sector-specific tariffs, should they be
implemented, with mitigation options identified in the supply chain
and productivity initiatives. The company will continue to monitor
and review developments related to this situation.
2021-2026 and 2031 Outlooks
In
February 2025 GSK set out improved outlooks for 2031. Please see
2024 full year and fourth quarter results on gsk.com(1).
Assumptions and basis of preparation related to 2025 Guidance,
2021-26 and 2031 Outlooks
In
outlining the guidance for 2025, and outlooks for the period
2021-26 and for 2031, the Group has made certain assumptions about
the macro-economic environment, the healthcare sector (including
regarding existing and possible additional governmental legislative
and regulatory reform), the different markets and competitive
landscape in which the Group operates and the delivery of revenues
and financial benefits from its current portfolio, its development
pipeline and restructuring programmes.
2025 Guidance
These
planning assumptions as well as operating profit and earnings per
share guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made) and no
change in the Group’s shareholdings in ViiV Healthcare. The
assumptions also assume no material changes in the healthcare
environment or unexpected significant changes in pricing or trade
policies as a result of government or competitor action. The 2025
guidance factors in all divestments and product exits announced to
date.
2021-26 and 2031 Outlooks
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity assume
the delivery of revenues and financial benefits from its current
and development pipeline portfolio of medicines and vaccines (which
have been assessed for this purpose on a risk-adjusted basis, as
described further below); regulatory approvals of the pipeline
portfolio of medicines and vaccines that underlie these
expectations (which have also been assessed for this purpose on a
risk-adjusted basis, as described further below); no material
interruptions to supply of the Group’s products; successful
delivery of the ongoing and planned integration and restructuring
plans; no material mergers, acquisitions or disposals or other
material business development transactions; no material litigation
or investigation costs for the company (save for those that are
already recognised or for which provisions have been made); and no
change in the shareholdings in ViiV Healthcare. GSK assumes no
premature loss of exclusivity for key products over the
period.
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity also
factor in all divestments and product exits announced to date as
well as material costs for investment in new product launches and
R&D. Risk- adjusted sales includes sales for potential planned
launches which are risk-adjusted based on the latest internal
estimate of the probability of technical and regulatory success for
each asset in development.
Notwithstanding
our guidance, outlooks and expectations, there is still uncertainty
as to whether our assumptions, guidance, outlooks and expectations
will be achieved.
All
outlook statements are given on a constant currency basis and use
2024 average exchange rates as a base (£1/$1.28,
£1/€1.18, £1/Yen 193).
(1)
https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, and
expectations described in this report are achievable based on those
assumptions. However, given the forward-looking nature of these
guidance, outlooks, and expectations, they are subject to greater
uncertainty, including potential material impacts if the above
assumptions are not realised, and other material impacts related to
foreign exchange fluctuations, macro-economic activity, the impact
of outbreaks, epidemics or pandemics, changes in legislation,
regulation, government actions or intellectual property protection,
product development and approvals, actions by our competitors, and
other risks inherent to the industries in which we
operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All
guidance, outlooks and expectations should be read together with
the guidance and outlooks, assumptions and cautionary statements in
this Q1 2025 earnings release and in the Group's 2024 Annual Report
on Form 20-F.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2024. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
Independent review report to GSK
plc
Conclusion
We have
been engaged by GSK plc (“the company”) to review the
condensed financial information in the Results Announcement of the
company for the three months ended 31 March 2025.
The
condensed financial information comprises:
|
|
|
|
●
|
the
income statement and statement of comprehensive income for the
three month period ended 31 March 2025 on page 22 and
23;
|
|
●
|
the
balance sheet as at 31 March 2025 on page 24;
|
|
●
|
the
statement of changes in equity for the three-month period then
ended on page 25;
|
|
●
|
the
cash flow statement for the three-month period then ended on page
26; and
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 27 to 35 that
have been prepared applying consistent accounting policies to those
applied by GSK plc and its subsidiaries (“the Group”)
in the Annual Report 2024, which was prepared in accordance with
UK-adopted international accounting standards in conformity with
the requirements of the Companies Act 2006 and the International
Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Boards (IASB).
|
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three months ended 31 March 2025 is not
prepared, in all material respects in accordance with the
accounting policies set out in the accounting policies and basis of
preparation section on page 32.
Basis for Conclusion
We
conducted our review in accordance with International Standard on
Review Engagements (UK) 2410 “Review of Interim Financial
Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom (ISRE (UK) 2410). A review of interim financial
information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with
International Standards on Auditing (UK) and consequently does not
enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit.
Accordingly, we do not express an audit opinion.
As
disclosed on page 32, the annual financial statements of the
company are prepared in accordance with United Kingdom adopted
international accounting standards. The condensed set of financial
information included in this Results Announcement have been
prepared in accordance with the accounting policies set out in the
accounting policies and basis of preparation section on page
32.
Conclusion Relating to Going Concern
Based
on our review procedures, which are less extensive than those
performed in an audit as described in the Basis for Conclusion
section of this report, nothing has come to our attention to
suggest that the directors have inappropriately adopted the going
concern basis of accounting or that the directors have identified
material uncertainties relating to going concern that are not
appropriately disclosed.
This
Conclusion is based on the review procedures performed in
accordance with ISRE (UK) 2410, however future events or conditions
may cause the entity to cease to continue as a going
concern.
Responsibilities of the directors
The
directors are responsible for preparing the Results Announcement of
the company in accordance with the Disclosure Guidance and
Transparency Rules of the United Kingdom’s Financial Conduct
Authority.
In
preparing the Results Announcement, the directors are responsible
for assessing the company’s ability to continue as a going
concern, disclosing as applicable, matters related to going concern
and using the going concern basis of accounting unless the
directors either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do
so.
Auditor’s Responsibilities for the review of the financial
information
In
reviewing the Results Announcement, we are responsible for
expressing to the company a conclusion on the condensed financial
information in the Results Announcement based on our review. Our
Conclusion, including our Conclusion Relating to Going Concern, are
based on procedures that are less extensive than audit procedures,
as described in the Basis for Conclusion paragraph of this
report.
Use of our report
This
report is made solely to the company in accordance with ISRE (UK)
2410. Our work has been undertaken so that we might state to the
company those matters we are required to state to it in an
independent review report and for no other purpose. To the fullest
extent permitted by law, we do not accept or assume responsibility
to anyone other than the company, for our review work, for this
report, or for the conclusions we have formed.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
29
April 2025
|
|
|
Glossary
|
|
|
|
|
Terms used in the Announcement
|
Brief description
|
|
2
L
|
2nd
line
|
|
ACIP
|
Advisory
Committee on Immunization Practices
|
|
ADC
|
Antibody-drug-conjugates
|
|
ADP
|
Adenosine
diphosphate
|
|
AMP
|
Average
manufacturer price
|
|
ASO
|
Antisense
oligonucleotide
|
|
AS03
|
Adjuvant
system 03
|
|
Bnab
|
Broadly
neutralising antibody
|
|
CCL
|
Contingent
consideration liability
|
|
CDC
|
Centre
for Disease Control and Prevention
|
|
CMS
|
Centre
for Medicare & Medicaid Services
|
|
COPD
|
Chronic
obstructive pulmonary disease
|
|
CROI
|
Conference
on Retroviruses and Opportunistic Infections
|
|
CRSwNP
|
Chronic
rhinosinusitis with nasal polyps
|
|
DTG
|
Dolutegravir
|
|
EGPA
|
Eosinophilic
granulomatosis with polyangiitis
|
|
ESOP
|
Employee
share ownership plan
|
|
GIST
|
Gastrointestinal
stromal tumours
|
|
HBV
|
Hepatitis
B virus
|
|
HES
|
Hypereosinophilic
syndrome
|
|
IBATi
|
Ileal
bile acid transporter inhibitor
|
|
Insti
|
Integrase
nuclear strand transfer inhibitors
|
|
IRA
|
Inflation
Reduction Act
|
|
JAK
|
Janus
kinase inhibitor
|
|
JAK1/JAK2
and ACVR1
|
once
a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1)
inhibitor
|
|
LA
|
Long
acting includes Cabenuva and
Apretude
|
|
MAPS
|
Multi
antigen presenting system
|
|
MDS
|
Myelodysplastic
Syndromes
|
|
MGMT
glioblastoma
|
methylated
DNA protein cysteine methyltransferase
|
|
MMR/V
|
Measles,
mumps, rubella and varicella
|
|
mRNA
|
messenger
ribonucleic acid
|
|
OA
|
Older
adults
|
|
OECD
|
Organisation
for Economic Co-operation and Development
|
|
Oral
2DR
|
Oral 2
drug regimen includes Dovato and Juluca
|
|
PARP
|
a Poly
ADP ribose polymerase
|
|
PD-1
|
a
programmed death receptor-1 blocking antibody
|
|
PK
|
Pharmacokinetics
|
|
PYS
|
Peak
year sales
|
|
Q4M
|
every 4
months
|
|
Q6M
|
every 6
months
|
|
RCC
|
Refractory
chronic cough
|
|
RNS
|
Regulatory
news service
|
|
RSV
|
Respiratory
syncytial virus
|
|
SCLC
|
small
cell lung cancer
|
|
SITT
|
Single
inhaler triple therapy
|
|
TIGIT
|
T cell
immunoreceptor with Ig and ITIM domains
|
|
TIM3
|
T-cell
membrane protein-3
|
|
TSLP
|
Long-acting
anti-thymic stromal lymphopoietin monoclonal
|
|
ULA
|
Ultra
long acting
|
|
uUTIs
|
uncomplicated
urinary tract infections
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
April 30, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|